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ABSTRACT 
This thesis describes the results from a series of 
studies designed to evaluate the gastrointestinal 
transit of oral dosage forms. The transit of placebo 
pellet and tablet formulations was monitored using the 
technique of gamma scintigraphy. The formulations were 
radiolabelled with either technetium-99m or indium-lil. 
Four parameters, two physiological and two 
pharmaceutical, were selected for investigation. All 
the studies were conducted in healthy male volunteers • 
. 
The first study examined the influence of the 
supine position on the gastric emptying of pellets in 
fasted and fed subjects. There was no marked 
difference between the supine and control gastric 
emptying data. As would be expected, food had a 
significant effect on gastric emptying. 
The influence of the time of day of administration 
on the gastrointestinal transit of pellets was 
investigated in fasted subjects. Transit of the 
pellets was not affected by their time of 
administration. 
The effect of the putative bioadhesive, 
polycarbophil, on the gastrointestinal transit of a 
pellet formulation was studied in fasted subjects. The 
pellets emptied from the stomach, rapidly and in an 
exponential manner. 
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A set of studies was conducted to evaluate the 
transit of tablets in fed and fasted subjects. Tablet 
size did not affect gastric emptying, although there was 
an increase in the variability of gastric emptying with 
increasing tablet size. Food had a marked effect on 
gastric emptying. The rate of emptying was related to 
the energy content of the meal. Tablet size did not 
appear to be a determinant of transit through the 
ileocaecal sphincter. The colon transit and dispersion 
of the tablets was examined. Neither the ingestion of 
food nor defecation appeared to alter the rate of transit 
through the colon. 
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CHAPTER ONE: 
INTRODUCTION 
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1.1 Outline 
This introduction provides a review of topics 
pertinent to my thesis. I shall begin by discussing 
relevant aspects of gastrointestinal (GI) physiology, 
with an emphasis on GI motility. Techniques to measure 
GI transit will be revised, with particular reference to 
the technique of gamma scintigraphy. Mention will be 
made of the design and development of controlled release 
(CR) dosage forms, and I shall consider the import of GI 
physiology to the design of CR dosage forms. A review of 
the GI transit of oral dosage forms will be made. 
Finally, the aims and objectives of the thesis will be 
discussed. 
1.2 Gastrointestinal Physiology 
The vast span of this subject forces me to 
concentrate on the topic of gastrointestinal (GI) 
motility, with a brief mention of GI anatomy. A more 
comprehensive discussion of GI physiology and function 
can be found in several texts (1,2,3). 
1.2.1 The Stomach 
The first detailed investigation of the human 
stomach was made by William Beaumont (4). In 1882, he 
had the opportunity to study the functions of the stomach 
through a gun-shot wound. Our methods of study, and our 
knowledge have measurably advanced since then. 
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1.2.1.1 Structure and function 
Material enters the stomach via the oesophagus. 
Oesophageal transit depends on the physical nature of the 
bolus and on contractile activity (5). Gravity 
influences the movement of liquids, whilst other 
materials rely on repetitive contractions to sweep the 
bolus into the stomach. 
The stomach performs four main functions (6): 
i. acts as a reservoir; 
ii. mixes ingested material with gastric 
secretions; 
iii. propels material into the small intestine; 
iv. acts as an antibacterial barrier. 
However, despite the complexity of gastric function, the 
stomach is not a vital organ. 
The stomach accomplishes its motor activity by an 
interaction of two distinct regions, the proximal and 
distal regions (7) (Figure 1.1). The dividing line 
between these regions is determined by myoelectric and 
motor criteria. 
The proximal stomach is primarily concerned with the 
receipt and storage of food, and transfer of chyme to the 
duodenum. The contractions of the proximal stomach serve 
to regulate intragastric pressure, as well as propelling 
gastric contents and accommodating swallowed food. The 
proximal stomach has the property of receptive 
Pyloric 
sphincter 
\ 
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Oesophagus 
Cardiac - ~ ~
sphincter 
Lesser 
curvature 
Antrum 
Figure 1.1 Anatomical structure of the stomach 
Greater 
CUIvature 
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relaxation, which allows the stomach to fill without 
large increases in intergastric pressure (B). Slow, 
steady contractions which press contents distally have a 
major role in emptying liquids. This is thought 
primarily to be a function of the pressure gradient 
between the stomach and duodenum (9). Simple solutions 
have been shown to empty rapidly in either an exponential 
fashion (10) or as a linear function of the square root 
of the volume remaining in the stomach (11). The 
contractions of the proximal stomach are regulated 
through an inhibitory vagal system (12), hormones (eg. 
motilin and gastrin) and by locally released substances 
(eg. histamine). 
The main functions of the distal stomach is to mix 
and triturate gastric contents, and regulate the emptying 
of solids (Figure 1.2). The characteristic contractions 
of the distal stomach is the peristaltic wave. As the 
waves sweep distally, the velocity of propagation 
increases so the entire gastric wall of the distal antrum 
appears to contract simultaneously - terminal antral 
contraction. Postprandial waves do not occlude the 
gastric lumen, and propel chyme near the gastric wall 
toward the pylorus, but allow more central contents to 
pass backward. The contractions are vagally and 
sympathetically mediated, in response to stretch, 
mechanical and pH perturbations. Hormones (eg. gastrin) 
-8-
Antral contractions 
mix and triturate 
digestible solids. 
Wave moves solids 
to distal antrum. 
Pylorus constricts, 
only small particles 
and liquids pass 
through; larger 
particles retropelled. 
Py loms relaxes, 
process repeats. 
Figure 1.2 Contractions of the fed stomach 
... 
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and locally released chemicals (eg. histamine) also have 
a regulatory role. 
The consequences of the contractions of the distal 
stomach are the mixing of gastric chyme with gastric 
juices, and trituration of gastric solids. Chyme is 
propelled towards the pylorus, and liquid in the chyme 
passes through to the duodenum, whilst solids are 
retained. The terminal antral contraction closes the 
pylorus, trapping the remaining liquid with the solids. 
An antral systole compresses the antral contents and 
causes retropulsion into the corpus of the stomach. This 
cycle continually repeats, mixing and triturating gastric 
solids. Eventually, small solid particles, O.lmm in 
size, will become suspended in the liquid phase of the 
chyme and pass through to the duodenum (13). The 
emptying of solids is largely determined by their 
resistance to flow across the pylorus, even if a large 
pressure gradient exists. Antral and pyloric 
contractions determine the magnitude of the resistance at 
the junction, and hence their role in the emptying of 
solids. Digestible solids empty in a linear fashion at a 
slower rate than liquids (14). They are also subject to 
a lag phase due to the triturating process. Dozois et al 
(15) illustrated the importance of the antrum in 
regulating the gastric emptying (GE) of solids, by 
performing a distal antrectomy in dogs. The operation 
resulted in premature and rapid emptying of solids. 
-10-
The pyloric junction acts as an integral part of the 
terminal antrum. The small diameter of the lumen 
provides continence of gastric solids. As solids are 
swept distally, the junction closes preventing particles 
larger than about 2mm from leaving the stomach (16). The 
junction also remains closed when contractions occur in 
the proximal duodenum, thus preventing retrograde 
movement of duodenal contents. 
1.2.1.2 Determinants of gastric emptying 
Factors which modify the pattern of gastric emptying 
can be divided into three groups, physiological, 
pathalogical and pharmacological. A number of reviews 
discussing these influences on gastric emptying are 
available (16,17,18,19). 
The primary determinant of liquid emptying is volume 
(20). Distension of the stomach is the only natural 
stimulus that increases the rate of gastric emptying 
(19). Thus, the greater the ingested volume, the faster 
the rate of emptying (20). Similarly, increasing the 
meal weight, at constant caloric content, increases the 
emptying of solid f ~ o d d <Aj). Most other factors that 
influence gastric e m ~ y i n g g do so by inhibiting the 
activity of the gastric pump. This inhibition is 
mediated through a number of receptors located in the 
duodenum and jejunum (22) - acid receptors, osmotic 
receptors, fat receptors and L-tryptophan receptors. The 
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receptors sense the nature of the just emptied chyme, and 
activate mechanisms which alter the rate of emptying of 
subsequent material. This control ensures that the small 
intestine does not become overburdened. 
The composition of chyme, its acidity, osmolarity 
and fat or amino acid content, probably exerts the most 
significant effect on gastric emptying. Neutral, 
isoosmolar and calorically inert solutions empty quite 
rapidly (23). Hypertonic solutions containing fats, acid 
and some amino acids all retard gastric emptying by 
action of the duodenal receptors. Solutions with high 
acid concentrations cause a more profound inhibitory 
effect than those of low concentrations (24). The 
inhibitory effect of an acid can be related to its 
molecular weight in that, acids with high molecular 
weight cause less retardation than those with low 
molecular weight. In general, increasing the osmolarity 
of a solution results in slower emptying (25). The 
inhibitory effect of fatty acids is determined by the 
fatty acid chain length, with chain lengths of 10-14 
carbons causing the greatest delay (26). Amino acids 
exert their effect by the osmolarity of the solution. 
However, L-tryptophan appears to have a specific 
inhibitory effect, suggesting the presence of a specific 
receptor (27). 
The greater the energy content of food, the slower 
the rate of emptying (28). The rate of emptying is such 
• 
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that the number of calories delivered to the duodenum 
remains constant. Thus, carbohydrates empty faster than 
proteins, which empty faster than fats. However, 
isocaloric amounts of each, empty at the same rate (29). 
Nevertheless, increasing the caloric content of a meal 
will not overcome the enhancing effect of meal weight 
(21). Carbohydrates and amino acids, except 
L-tryptophan, retard gastric emptying via the 
osmoreceptors, and fats slow emptying via the fat 
receptors (22). 
The viscosity of a meal appears to be an important 
factor in gastric emptying (30,31). An increase in 
viscosity not only slows emptying, but significantly 
alters gastric sieving (32). 
Temperature effects on gastric emptying have not 
been extensively investigated. Ritschel and Erni (33) 
found capsules entered the small bowel more rapidly with 
a cold drink than a warm one. Bateman (34) observed only 
an initial rapid emptying for cold drinks, with no 
significant effect on subsequent emptying. 
The relationship of body size to the rate of gastric 
emptying has been investigated. Both body size and body 
area were inversely proportional to the rate of gastric 
emptying (35). Another study indicated obese men empty 
solids more rapidly than non-obese men, whilst both 
groups had similar patterns of liquid emptying (36). The 
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slower emptying of solids may have resulted from 
prolongation of the lag phase in obese subjects (37). 
Other factors known to alter gastric emptying 
include stress (38), posture (39), and sex of the subject 
(40). A relationship has been shown between gastric 
emptying ~ n d d the phase of the menstrual cycle (41), and 
also the stage of pregnancy (42). Solid and liquid 
emptying were significantly slower in older subjects than 
. 
in younger subjects, but this was not considered 
clinically significant (43). Gastric emptying is 
retarded by severe exercise, but hastened by mild 
exercise (44). Furthermore, the extent of retardation is 
a function of the level of the exercise, and not the type 
of exercise. 
One significant observation with consequences for GI 
studies, is that gastric emptying time is a variable 
process in healthy subjects, with significant inter- and 
intrasubject day-to-day differences (45). 
It should be remebered, that the control of gastric 
emptying not only serves digestion and transit, but is 
likely to have homeostatic features which influence 
feeding (46). 
Diseases which modify the rate of gastric emptying 
can be classified as either extrinsic or intrinsic (47). 
There have been few studies to illustrate the direct 
effect of extrinsic diseases on gastric emptying. In 
many cases the drug administered to treat the disease may 
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affect gastric emptying. However, diseases that 
apparently delay gastric emptying include diabetes 
mellitus (48), thyroid disease (49), and migraine (50). 
The data for intrinsic diseases is more conclusive. The 
disease states shown to affect gastric emptying include 
gastric ulceration (51), gastric dyspepsia (52), pyloric 
stenosis (53) and gastric carcinoma (54). 
A number of drugs have been shown to influence the 
rate of gastric emptying. Some drugs, such as atropine 
(55), propantheline (56), and morphine (57), reduce 
gastric motility. Other drugs, such as metoclopramide 
(58), and domperidone (59), increase the rate of 
emptying. Cigarette smoking accelerates the rate at 
which liquids leave the stomach (60), and high nicotine 
cigarettes delay the emptying of solid foods (61). It 
has been suggested that wine and beer delay gastric 
emptying, while spirits may promote emptying (62). 
1.2.1.3 Migrating myoelectric complex 
The patterns of gastric emptying discussed above 
relate to the stomach in the postprandial state. During 
fasting the stomach is ordinarily empty aside from 
swallowed saliva, mucus and cellular debris. In addition 
there may be particles of indigestible solid content left 
from the previous meal. A mechanism termed the migrating 
myoelectric complex (MMe), first described by Szursweski 
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(63), exists to empty this fasting content. The MMC 
exhibits four distinct phases: 
phase 1 - 45-60 mins of no contractions; 
phase 2 - 30-45 mins of intermittent contractions, 
phase 3 - 5-15 mins of powerful distal and 
proximal gastric contractions; 
phase 4 - 5 min transitory period back to phase 1. 
Each phase of the cycle migrates distally from the 
stomach to the terminal ileum, and takes about 2 hours to 
do so. Thus, when one phase 3 reaches the terminal ileum, 
another is begining in the stomach. The pylorus remains 
open when the waves approach allowing liquids and solids 
to be propelled out. The ability of phase 3 to so 
completely empty the stomach has earned it the name the 
"housekeeper wave" of the gastrointestinal tract (GIT). 
Abolition of the cycle occurs promptly with feeding and a 
normal meal causes disruption of the MMC for about 3-4 
hours (64). The disruption is mediated through both 
neural and hormonal action (65). 
1.2.2 The Small Intestine 
Detailed ~ n v e s t i g a t i o n s s of the small intestine 
became possible with the advent of radiographic 
techniques. The studies co'nducted by Cannon (66) early 
this century still provide much of our basic 
understanding of the small intestine. 
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1.2.2.1 Structure and function 
The small intestine is a long tubular structure, 
300-400cm, that extends from the stomach to the caecum. 
Although the small intestine is one continuous organ, it 
is normally considered as three parts, duodenum, jejunum, 
and ileum. The diameter of the intestine gradually 
decreases from the proximal to the distal end. 
The small intestine is the major area of absorption 
of water, nutrients and electrolytes. Contractions of 
the small intestine musculature bring about: 
i. mixing of foodstuffs with digestive enzymes; 
ii. circulation of the intestinal contents to 
ensure contact with the absorptive cells of 
the mucosa; 
iii. net aboral movement of chyme. 
The manner of movement depends on the volume and 
composition of food, although little is known about these 
characteristics in each region of the intestine. It is 
known that duodenal contents are more voluminous and less 
viscous than ileal contents. Nonpropulsive contractions 
serve to mix and locally circulate the contents by 
rhythmic segmentation, causing oral and aboral movements, 
but no net propulsion. Propulsive contractions, or 
peristalsis, propel the intestinal contents in an aboral 
direction over varying distances, but cause little mixing 
(67) • 
~ 1 7 7
A comprehensive study of small intestine transit 
times in a number of subjects between the ages of 1-25 
years, reported mean transit times of 2.75-3h (68). A 
detailed study on the flow rate, flow velocity and 
composition of intestinal contents, suggested that 
laminar flow occurs in the small intestine (69). 
Furthermore, a velocity gradient exists down the 
intestine, with flow rates decreasing in the distal 
portion of the intestine. 
Contractions of the small intestine are due to the 
activities of smooth-muscle cells. These contractions 
are dependent on the intrinsic properties of the cells, 
intrinsic nerve plexuses, extrinsic para- and sympathetic 
nerves, and locally released chemicals (eg. gastrin, 
acetylcholine). 
1.2.2.2 Determinants of intestinal transit 
Unlike the stomach, the small intestine does not 
differentiate between solids and liquids, and both 
materials move through the intestine at the same rate 
(70). However, liquids reach the colon faster than 
solids, when considering stomach to caecum transit, due 
to the difference in gastric emptying. Furthermore, 
changes in intestinal transit can occur independently of 
changes in gastric emptying (71). These changes are 
governed by dietary factors. 
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A recent hypothesis proposes the presence of a 
feedback mechanism which controls gastric emptying and 
small bowel transit (72). This "ileal brake" is located 
in the distal ileum, and would serve to optimise the time 
available for absorption. The mechanism operates by 
detecting unabsorbed fat or protein, and via an 
undetermined mediator, would delay both gastric emptying 
and intestinal transit (73). Spiller et al (74) gave 
further credence to the hypothesis, by showing that an 
infusion of intra1ipid delayed transit of 
bromosulphthalein. A similar study illustrated the 
effect on carbohydrate absorption by the presence of fat 
in the ileum (75). The importance of the terminal ileum 
in controlling intestinal transit was described by Neal 
et al (76). A rapid small bowel transit was observed in 
patients who had undergone ileal resection. 
Apart from the presence of fat or protein in a meal, 
the amount of unabsorbable carbohydrate (eg.lactu10se) in 
the meal appears to have a profound affect on intestinal 
motility (77). An accelerated transit time probably 
resulted from an increase in luminal volume and an 
osmotic effect. 
As with gastric emptying, the menstrual cycle 
influences intestinal transit, with transit being slower 
in the luteal phase and faster after menstruation (41). 
Moderate exercise does not appear to affect small bowel 
transit (78), whilst stress accelerates transit (38). 
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Patients suffering from diarrhoea show a significant 
acceleration in intestinal motility (79), although this 
could be stress related. Conversely, patients suffering 
from constipation show delays in small bowel transit 
(80). 
Drugs known to reduce intestinal motility include 
morphine (81) and loperamide (79). Few drugs have been 
shown to accelerate intestinal transit, although 
metoclopramide is regarded to have a significant effect 
(82). Intravenous administration of metoclopramide 
caused a 
significant increase in the rate of travel of a capsule, 
but only in the proximal intestine (83). 
Finally, the duration of transit of a meal through 
the small bowel will influence the extent of absorption 
(84). However, it appears that absorption cannot be 
predicted solely from transit patterns, but depends on 
the agent or event that alters the transit (79). 
Absorption is inhibited to a greater extent by agents 
that increase intestinal volume, than by agents that 
directly stimulate propulsion. The implications for drug 
adminstration are profound. 
1.2.2.3 Migrating myoelectric complex 
The existence of the MMC was first demonstrated in 
the small intestine of fasting dogs (63,85), and the 
basic pattern has been described above. Control of the 
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MMC is thought to be mediated through hormones, eg. 
motilin, and extrinsic nerves (86). Wingate et al (87) 
have proposed the presence of an intrinsic biological 
clock, possibly located in the small bowel wall, which 
controls the periodic activity of the intestinal MMC, 
whereas gastric MMC are controlled by an extragastric 
mechanism. 
Intestinal MMC differ from gastric MMC, in that 
gastric MMC occur in the fasted state when the stomach is 
devoid of digestible matter, whilst intestinal MMC appear 
to have a role in the propulsion of intestinal contents. 
Code and Schlegel (88) illustrated the interdigestive 
propulsion of phase 3 using cineradiography techniques. 
It is accepted that this propulsive activity is not the 
primary force for transit, but may act to prevent orad 
transit of contents (89). Another proposal for the 
propulsive phases is that they are necessary to prevent 
bacterial overgrowth of the small bowel during fasting 
(90). Despite the uncertainty about the role of the 
propulsive phase of the MMC, the pattern of contractions 
will have a marked influence on intestinal transit and 
digestion (91). 
1.2.3 The I1eocaeca1 Sphincter 
The ileocaecal sphincter (ICS) is an anatomically 
distinct boundary between the small intestine and colon 
(91). The ICS was apparently first described by Bauhin, 
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in 1579, as a musculature structure rather than a 
mechanical sphincter (92). Interest in the functions of 
the sphincter was later renewed by Alvarez (93), Cohen 
(94), and more recently by Quigley and colleagues (95). 
1.2.3.1 Structure and function 
The ICS is apparent as a thickening of the 
musculature of the last few centimetres of the ileum. In 
man, a portion of the ileum projects into the caecum and 
is surrounded by colonic musculature. The res satisfies 
the four main criteria used to define sphincters of the 
GIT, ie. it exhibits a segment of tonic pressure; relaxes 
with distension of the ileum; contracts with distension 
of the proximal colon: and responds to nerve stimulation 
differently from adjacent Gr smooth-muscle (95). 
However, some observers have failed to detect a high 
tonic pressure at the human ICS (96). The tone of the 
rcs is regulated by electrical activity, neural activity 
and possibly hormonal action. 
The function and importance of the ICS are not 
confirmed. The sphincter may act to: 
i. regulate transit of material from the ileum to 
the colon; 
ii. prevent the reflux of colonic content into the 
ileum: 
iii. serve as a barrier to bacterial reflux from 
the colon. 
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The regulatory role controlling flow of material into the 
colon seems the most likely. However, there is much 
debate as to the nature of this flow. 
Several studies have shown an increased activity in 
the ileocaecal region within minutes of food ingestion 
being accompanied by expulsion of ileal contents into the 
colon - the gastroileal reflex (97,98). 
Spiller et al (99) concluded that postprandial flow 
of material across the ICS was regular and rapid, whilst 
transit before eating was slow and erratic. They also 
suggested a reservoir function for the terminal ileum 
during the low flow rates. Scintigraphic measurements of 
ileocolonic transit suggest that transit often occurs as 
a bolus in both the fed and the fasting state (100). The 
intermittent nature of transit across the ICS influences 
the colon's ability to absorb dietary residues, 
secretions, and water (101). Furthermore, the absorptive 
capacity of the colon is readily overloaded by rapid 
infusion of fluid (102). These observations point to a 
regulatory role for the ICS, to achieve maximum colonic 
absorption. 
The terminal ileum differs from the rest of the 
small intestine with regard to MMC activity. Studies 
have shown that phase 3 contractions become disorganised 
in the terminal ileum, and a single propulsive 
contraction not related to the MMC propels ileal contents 
into the colon (89). It has been suggested that in the 
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fasted state, this propulsive contraction could be 
related to phase 2 activity (100). A comprehensive study 
on the motility of the terminal ileum not only observed 
both the absence of phase 3 activity and the presence of 
a propulsive contraction, but also identified discrete 
clustered contractions (103). The relevance of these 
clustered contractions to the transit of ileal contents 
remains unclear. 
The role of the res in regulating the flow of 
material into the colon is not completely defined. 
Nevertheless, both the postulated reservoir function and 
bolus movements have implcations for drug delivery to the 
colon. 
1.2.4 The Colon 
The colon has been studied less than other portions 
of the alimentary canal. This has been due to the 
considerable interspecies variations in the anatomy of 
the colon, the complexity of its functions, and the 
presence of microbial flora which complicates the 
experimental approaches to colonic function (104). 
1.2.4.1 Structure and function 
The human colon is about 1.5m long and is generally 
described in several parts: appendix, caecum, ascending 
colon, transverse colon, descending colon, sigmoid colon, 
rectum and anus (Figure 1.3). Throughout its length, the 
C a e c u m - ~ ~
-24-
Part of wall 
removed to show 
ileocaecal valve 
Descending -
colon 
~ - ; - - A n u s s
Figure 1.3 Anatomical structure of the colon 
Splenic 
flexure 
Sigmoid 
colon 
-25-
colon is a sacculated organ, achieved by the arrangement 
of the outer muscle coats. The colon has a variety of 
functions: 
i. the maintenance of electrolyte and fluid 
balance: 
ii. provision of an absorption site for nutrients: 
iii. digestion and metabolism of dietary material: 
iv. formation of faeces: 
v. temporary storage of faeces until elimination 
is convenient. 
All segments of the colon have the capacity both to 
propel and prevent too rapid a progression of contents. 
This storage function facilitates digestion, reabsorption 
of ileal fluids and production of faecal mass. 
Furthermore, t h i ~ ~ property makes it more appropriate to 
measure colon transit time in days rather than in hours 
(105). Ritchie (106) observed that healthy subjects with 
normal bowel habits moved the contents of the right 
colon, under resting conditions, at a rate of lcm/h. 
Studies have shown that stools are retained in the right 
half of the colon (107), although a recent study suggests 
that the transverse colon, is the primary site of storage 
(108). 
The contractions of the colon can be divided into 
three basic patterns, which occur in distinct regions: 
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i. Ring contractions of 2-8 minutes occuring at 
15 minute intervals, which serve to mix and churn the 
contents in the caecum. Entry of new material from the 
ileum causes a brief period of strong contractions in the 
caecum and ascending colon, pushing the contents towards 
the rectum. 
ii. Co-ordinated peristalsis in the middle part of 
the colon of segmented or haustral contractions. These 
contractions are either stationary or propagate very 
slowly in an oral or aboral direction. However, they 
have a net propulsive role towards the rectum. 
iii. Strong contractions of the sigmoid colon and 
rectum which move contents slowly towards the anus and 
serve to empty the colon. 
The control of colonic segmental and propulsive 
activity appears to be very complex, and is mediated 
through myogenic factors, intrinsic and extrinsic 
innervation, and hormonal factors (109). 
1.2.4.2 Determinants of colonic motility 
Ingestion of food is the main physiological stimulus 
of colonic motor activity, often referred to as the 
"gastrocolic reflex" (110). A rapid increase in 
contractile activity occurs after eating, the degree of 
which depends upon the caloric content and the nature of 
the nutrients. Fat produces a much stronger stimulation 
of colonic activity than protein or carbohydrate (109). 
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Ingestion of crude fibres shortens transit time 
significantly. However, addition of large amounts of 
fibre to the diet regulates bowel habits. Thus, subjects 
with a slow transit time develop a faster one, and vice 
versa (Ill). 
A number of drugs are known to affect colonic 
transit. Laxatives (112) and cholinergic agents (113) 
generate colonic peristalsis which propagate mass 
movement of contents, and accelerate transit. Calcium 
antagonists (eg. nifedipine) decrease the postprandial 
activity (114). A recent paper reports that oleic acid 
induces accelerated transit and abnormal motility in the 
colon (115). 
Other factors that alter colonic motility include 
stress, distension of the colon, and many disease states 
(116). 
1.2.4.3 Pathology of the colon 
Interest has recently developed in formulating oral 
drug delivery systems for the local release of drugs used 
in the treatment of diseases of the colon. A brief 
outline of common abnormalities of colonic motility would 
identify those disorders which would benefit from local 
rather than systemic drug action. 
i. Irritable Bowel Syndrome (IBS). This is 
probably the most common disease of the colon, and leads 
to abdominal pain, constipation and diarrhoea (117). The 
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aetiology of IBS is thought to be a disordered motor 
function of the bowel, caused by stress. Treatment 
relies on identification and modification of the stress 
factors, as well as using drugs to treat anxiety, 
depression and colonic motility. 
ii. Colonic Diverticular Disease (COD). In this 
disease, small outpouches of the mucosa form through the 
muscle wall, and there is a raised intraluminal pressure 
due to disordered muscle activity (110). Its occurence 
is common in western society, and appears to be related 
to the amount of fibre in the diet. Treatment consists 
of a high roughage diet, and the use of antispasmodics 
(eg. peppermint oil (118» to reduce pain and discomfort. 
iii. Ulcerative Colitis and Crohn's Disease. Both 
these conditions are similar in their presentation, 
pathology and treatment. The diseases are possibly 
immunological in nature, and some evidence suggests a 
genetic influence (119). Ulcerative colitis involves the 
rectum, although the diseased area may spread proximally 
as a continuous band from the rectum. Crohn's disease is 
often present as a discontinuous inflammation of the 
bowel. Drug treatment involves the use of 
corticosteroids, and the local action of 5-aminosalicylic 
acid (5-ASA) (120). 
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1.3 Controlled Release Technology 
1.3.1 History of Controlled Release 
The notion that a dosage form can be other than 
simply a dose of drug, has only recently attracted 
attention. Advances in pharmacology and pharmacokinetics 
have demonstrated the importance of drug release rates 
and absorption in determining therapeutic results in 
systemic treatment (121). These advances have led to the 
development of dosage forms with specified or controlled 
drug delivery rates. 
Dosage forms with modified release rates are not 
entirely new. The first coated pills can be traced to 
about A.D. 900, when Rhazes recommended a mucilage 
coating (122). This technique was adopted by the 
Europeans in the '10th century, in the form of gold-, 
si1ver- and pearl-coated pills. Although these coatings 
were designed to mask bitter tastes and improve 
appearance, they did alter the release of drug. Advances 
in coating technology in the late 1800s saw the advent of 
sugar-coated and enteric-coated pills. These coating 
methods led to the development of the repeat action 
tablet (123), consisting of a core tablet sealed with an 
enteric material followed by a second drug dose in a 
sugar-coating layer. It was not until 1938, however, 
that Lipowski patented the first oral sustained release 
preparation (124). His formulation consisted of a number 
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of small coated beads, which gave a slow and constant 
release of drug. This idea was later developed by Blythe 
(125), and was the basis for the first marketed sustained 
release (SR) product in 1952 (126). 
Unfortunately, the proliferation of modified release 
formulations since that date, has created a problem of 
terminology (127). Controlled release is now the popular 
term to describe these formulations, since it implies a 
predictable and reproducible release rate, whilst SR 
suggests only a prolonged release of drug (128). 
However, neither term considers the physiological 
variables, such as GI transit, that will influence drug 
bioavai1abi1ity. 
The controlled release administration of drug is not 
restricted to the oral route. Systems have been 
developed for the transdermal (129), ocular (130), 
vaginal (131) and parentra1 (132) routes. These devices 
provide a localised depot of drug, with a rate-controlled 
release into the systemic circulation. Physiological 
influences are minimised due to the very design of the 
systems. The eventual design of such controlled release 
delivery systems (COOS) (133) for the oral route, will 
require an increased understanding of gastrointestinal 
tract (GIT) physiology (134). 
1.3.2 Rationale for Controlled Release 
-31-
The primary reasons for developing an oral 
controlled release formulation are listed below: 
i. Maintain a steady therapeutic drug 
concentration in the systemic circulation and tissue 
cells (135). Conventional dosage forms often require 
high doses to achieve a therapeutically effective 
concentration. This massive dosing can elicit 
undesirable toxicological effects. Furthermore, the peak 
and trough fluctuations common with conventional drug 
administration, can lead to periods of no therapeutic 
effect. 
ii. Reduced frequency of dosing (136). The 
advantage of a single daily dose is particularly suitable 
for psychiatric patients, who have a high failure rate in 
taking prescribed drugs (137). 
iii. Improved patient compliance (138). This 
probably results from the convenient dosing regimes and 
the reduced side-effects. 
iv. Economic advantage (139). Initial unit costs 
of CR formulations are usually greater than conventional 
dosage forms. However, the average cost of treatment 
over an extended period of time is less. Economy also 
results from a decrease in nursing time/hospitalization. 
The major disadvantages of oral controlled release 
formulations are: 
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i. Accidental poisoning (140). This can result 
if the integrity of the controlled release system is 
breached, possibly due to incorrect administration by the 
patient, causing "dose dumping". 
ii. Reduced control of dosing (141). The 
flexibility of tailoring drug doses to individual patient 
requirements is reduced with CR formulations. 
Inter-patient variation in response to a formulation also 
becomes more difficult to resolve. 
Although the advantages of CR formulations appear to 
outweigh the disadvantages, not all drugs are ideal 
candidates for controlled release. Properties of drugs 
that preclude their use in CR formulations include: 
i. Size of dose (142). The practical constraints 
in formulating high dose drugs (eg. aspirin), favours the 
use of drugs with small doses. 
ii. Site of absorption (143). The drug should be 
absorbed throughout the length of the GIT, and not at 
specific absorption windows in the upper part of the gut 
(eg. iron). 
iii. Duration of action (144). Controlled release 
formulations offer no advantage for drugs whose half-life 
is longer than about 12 hours (eg. diazepam). 
iv. Rate of metabolism (145). Drugs with a high 
first-pass metabolism are poor canditates for CR systems 
(eg. levodopa). This is because many metabolic processes 
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are saturable, leading to a dose-dependent loss of drug 
and a marked reduction in bioavai1abi1ity. 
v. Toxicity. Controlled release formulations 
often contain a large dose of drug. Rapid release of a 
potent drug with a narrow therapeutic index (eg. digoxin) 
would result in a systemic toxic reaction. 
1.3.3 Oral Controlled Release Systems 
Oral controlled release systems are classified as 
either single-unit or mUltiple-unit doses (146). 
Single-unit preparations remain as a non-disintegrating 
unit throughout the GIT. Multiple-unit preparations are 
composed of many CR sub-units, formulated either in a 
capsule or as a tablet, designed to disperse throughout 
the GIT. These preparations offer a more reproducible GI 
transit than single-unit systems (147), but are often 
more expensive to manufacture (148). Liquid CR products 
have also been developed (149), but the difficulties in 
formulating such preparations normally makes them 
commercially nonviable. 
Controlled release of drug from the dosage form, 
either single-unit or multiple-unit, can be achieved by a 
variety of techniques. Generally, the system consists of 
a drug reservoir, a source of energy, and a rate 
controlling device (150). The energy required is 
provided by a concentration gradient between the drug 
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core and the surrounding fluid. The rate controlling 
device relies on specific physical mechanisms: 
i. Diffusion controlled systems. Drug is either 
encapsulated in a water-insoluble polymer (151) or 
dispersed in an insoluble matrix (152). The rate of 
release is dependent on the rate of drug diffusion from 
the system and is a zero-order process for encapsulated 
systems (153) but proportional to the square root of time 
for matrix systems (154). 
ii. Dissolution controlled systems. These are 
similar to the above, but drug dissolution and not 
diffusion is rate limiting. A constant release rate will 
be achieved if the surface area, concentration and 
diffusional pathlength can be maintained (155). 
iii. Osmosis controlled systems. These systems 
consist of a drug core, either solid or liquid, 
surrounded by a semipermeable membrane containing a small 
orifice (156). Selective entry of water dissolves the 
drug, and generates an internal pressure which forces the 
drug solution out of the orifice. Two products relying 
on this mechanism have been developed by the Alza 
Corporation, (a) OROS, designed for the delivery of solid 
drug (157); and (b) OSMET, designed for the delivery of 
semi-solids and liquids (158). The advantages of these 
products include their zero-order release rate, which is 
largely unaffected by the conditions in the GIT, and the 
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large category of drugs that can be formulated into 
osmotic systems (121). 
In summary, controlled release dosage forms offer a 
number of advantages over conventional drug 
administration. Several innovative mechanisms have been 
developed to achieve a constant and predictable release 
rate, but scant consideration has been given to the fate 
of the dosage form in the GIT. 
1.4 Techniques to Measure Gastrointestinal Transit 
A number of methods has been applied to investigate 
the performance of dosage forms in the GIT. These 
methods can be described as either invasive or 
non-invasive. Invasive techniques interfere with normal 
physiological processes, which makes them less suitable 
as investigative tools than non-invasive techniques. 
1.4.1 Invasive Techniques 
Early studies on the GI behaviour of dosage forms 
were primarily concerned with evaluating the performance 
of enteric coated tablets (159). These methods were 
later applied to the evaluation of other tablet 
formulations. Techniques such as the Yo-Yo method, which 
involved the withdrawal of tablets from the gut by means 
of a string attached to them (160), and induced vomiting 
(161), would have been particularly unpleasant for the 
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volunteer subjects. Other tests involved the detection 
of either dye markers or drug metabolites in the saliva 
. (eg. iodide from potassium iodide tablets (160»; in the 
urine (162) (eg. methylene blue (163»; and in the blood 
(164). These methods provided good estimates of drug 
absorption, but scant information on the GI behaviour of 
the tablets, other than the tablets must have 
disintegrated. 
The most common method of determining the in vivo 
performance of tablets was to incorporate radio-opaque 
material, usually barium sulphate, into the tablets, 
which enabled visualisation using X-rays (165). The high 
density of barium sulphate, which could affect gastric 
emptying, and the problems of safety associated with 
X-rays are major disadvantages of this method. 
Nevertheless, roentgenologic methods have been widely 
used to investigate the fate of timed-disintegration 
capsules (166), and of pellets (167). 
Mouth to caecum transit time can be estimated 
indirectly by the measurement of pulmonary hydrogen 
excretion. The method, known as the hydrogen breath 
test, features the administration of a nonabsorbable 
carbohydrate, 1actulose, which is converted to hydrogen 
by anaerobic bacteria in the colon. The level of 
hydrogen excreted in the breath can be measured by gas 
chromatography (168). The problems associated with this 
method include the large quantity of lactulose required 
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to produce a significant rise in hydrogen and the 
acceleration of intestinal propulsion caused by the 
strong osmotic stimulus exerted by this large quantity 
(169). Furthermore, some individuals may lack the 
intestinal flora required for the degradation of 
lactulose to produce hydrogen. Modifications to the 
method have been made with the use of 14C-lactulose, and 
the measurement of 14C02 in the breath (170). The 
negligible mass of carrier lactulose required alleviates 
the problem of accelerated intestinal transit. 
Other techniques include those routinely used for 
clinical investigations of the gut, such as gastroscopy, 
which allows visualisation of solid doses (171), and 
intubation methods such as aspiration and perfusion, for 
liquids and small particles (172, 173). However, these 
methods can cause much discomfort to the volunteers. 
1.4.2 Non-invasive Techniques 
An early study to measure GI transit used inert 
materials which were swallowed and subsequently recovered 
in the faeces (174). A similar idea was used by 
Bechgaard and Ladefoged (175), who recovered pellets from 
ileostomy bags. The problems with this method are that 
the recovery of the dosage forms maybe incomplete and 
ileostomy patients may have different GI characteristics 
from subjects with intact intestines. 
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Recent advances in diagnostic instrumentation has 
led to a number of direct, non-invasive methods. Gastric 
emptying of liquids can be measured by ultrasound (176). 
Since there are no ionising risks, the technique can be 
used safely in both men and women (177) and can be 
repeated on the same subject (178). However, the 
technique is restricted to measuring the gastric emptying 
of liquids. 
The gastric emptying of liquids can also be 
determined by measuring epigastric impedance (179). 
Gastric impedance rises when liquids of low conductivity 
are swallowed, and then drops as the liquid empties. The 
technique is regarded simpler and cheaper to operate than 
most other methods, as well as providing comparable 
results (180). However, gastric secretions could become 
a source of impedance error, as could changes in skin 
resistance due to anxiety or stress. More recently, 
Avill et al (181) described the use of applied potential 
tomography to follow the gastric emptying of liquids and 
semisolids. The method relies on the change in tissue 
resistivity during gastric emptying. 
These methods have little application to the study 
of the GI transit of solid doses, but provide valuable 
information about GI motility. The use of 
radiotelemetric capsules, however, would provide transit 
profiles that resemble the GI transit of large 
indigestible solids. These capsules either transmit a 
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continuous radio signal which is received by an external 
detector (182) or monitor the pH of the environment 
(Heidelberg capsule) (183). Gastric emptying of the 
latter is indicated by a sharp rise in pH, as the capsule 
moves from the acidic stomach to the more alkaline 
intestine. The performance of an enteric coated 
formulation was evaluated by attatching a coated buffer 
tablet to an Heidelberg capsule (184). Premature rupture 
of the coating in the stomach was detected by a rise and 
then a fall in gastric pH prior to gastric emptying. 
However, these methods can only give reliable information 
on the GI transit of the device, and cannot be used to 
determine the transit of multi-particulate formulations. 
The use of animal models to measure the GI transit 
time of dosage forms has been forwarded by Takahashi et 
al (185). It was reported that rabbits in which gastric 
emptying and gastric pH were controlled by special diet, 
had GI transit profiles similar to humans. The authors 
suggest that these rabbits could be used as a model for 
estimating the bioavailability of controlled release 
products in humans. 
1.4.3 Gamma Scintigraphy 
The technique of gamma scintigraphy has become the 
most popular method to investigate the GI performance of 
both food and pharmaceuticals. A gamma emitting isotope 
is incorporated into the test material, and is monitored 
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externally by measuring the radiation emitted. Griffiths 
et al (186), in 1966, were the first to demonstrate this 
technique, by monitoring the gastric emptying of 
chromium-51 labelled food using an automatic 
scintiscanner. Hansky and Connell (187) had previously 
used chromium-51 to measure total transit times, by 
administering radiolabelled chromium oxide powder and 
using a scintillation counter to measure the activity 
recovered in the stools. However, it was not until 1976 
that the technique was used to investigate the fate of 
pharmaceuticals in vivo. Alpsten et al (188) used two 
scintillation detectors to monitor the dispersion of 
radioactively labelled tablets. In an almost 
simultaneous publication, Casey et al (189) described the 
use of external scintigraphy to visualise the 
disintegration of technetium-99m labelled capsules. The 
same technique was later used to monitor the in vivo 
disintegration of tablets (190). 
1.4.3.1 The gamma camera 
Certain materials have the property of emitting a 
flash of light or scintillation when struck by ionising 
radiation. A scintillation detector detects ionising 
radiation by observing the scintillation induced in the 
material. The head of scintillation or gamma cameras 
commonly consists of a sodium iodide crystal, 40cm in 
diameter, activated with thallium, NaI(Tl). Pure sodium 
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iodide crystals do not normally scintillate at room 
temperature, but do so after the addition of thallium. 
The thickness of the crystal is restricted to about lcm. 
In a thick crystal, the depth of the flash of light will 
affect the intensity of light detected, whilst thin 
crystals will have poor detection efficiency (191). 
Coupled to the crystal is an hexagonal array of 
photomultiplier tubes, which detect the light pulses. 
The whole arrangement is encased in lead to shield the 
crystal from extraneous radiation. A package of 
electronics links the photomultiplier tubes to a computer 
and visual display unit. Information regarding the 
strength and position of the pulses are stored in the 
computer for subsequent analysis, and an image can be 
generated on the display unit (Figure 1.4). 
Gamma rays from the source are focused onto the 
detector by a lead collimator placed directly in front of 
the crystal. A number of collimators is available, 
including parallel-hole, converging and pinhole 
collimators. The latter are suitable for magnifying 
small objects such as the eye. Parallel-hole collimators 
are the most commonly used, and give a 1:1 correspondence 
of object and projection onto the scintillator (191). 
The collimator consists of many thousands of 
parallel-sided holes, which ensure that only parallel 
rays emitted from the source are detected. Parallel-hole 
collimators are available as low energy, medium energy 
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and high energy, depending on the thickness of the septa, 
and hence the number of holes. Low energy collimators 
have thin septa and thus many holes, which makes them 
more sensitive. The collimator used will depend on the 
photon energy of the isotope being used. A comprehensive 
account of gamma cameras can be found in a number of 
publications (192, 193). 
1.4.3.2 Radiopharmaceuticals 
A number of radionuc1ides are available for imaging 
purposes, but not all are ideal candidates. Factors such 
as the radiation energy, half-life, extent of particulate 
radiation, cost and availability must be considered. Low 
energy radiation is absorbed by the tissues, whilst high 
energy radiation raises problems in shielding the 
detector (194). The ideal energy range is considered to 
be between 100-250keV, although the use of appropriate 
collimators can extend this to 70-400keV. The half-life 
is important not only because of radiation doses to the 
subject, but must be sufficiently long to allow 
preparation of the radiopharmaceutical and perform the 
study (195). 
After taking the above criteria into account, only a 
few radionuc1ides are suitable for imaging studies. 
These can be divided into three categories according to 
their chemistry (194), native labels (eg. lIe); foreign 
covalent labels (eg. 755e ); and foreign metal-ion label 
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99m-(eg. ~ c ) . . Native labels generally have short 
half-lifes, and are prepared by a cyclotron. This 
restricts their use for studies on drug delivery systems, 
although they have been utilised in studies of tissue 
disposition of drug (196). Metal-ion nuclides most 
closely satisfy the essential criteria, which accounts 
for their extensive use in scintigraphy studies. The 
most popular of these is technetium-99m. The reasons for 
this popularity are its versatile chemistry, near ideal 
energy (140keV), low radiation dose, and suitable 
half-life (6.0h). Furthermore, it is readily available 
through the use of a portable generator (197) (Figure 
1.5). Other commonly used metal-ion nuclides include 
indium-Ill and indium-113m. A more complete review of 
radionuclides suitable for imaging has been given by 
Kelly (194). 
Having chosen a suitable radionuclide, an 
appropriate agent must be selected, which is 
radiolabelled with the isotope. Gastrointestinal studies 
require both solid-phase and liquid-phase markers. Apart 
from being nontoxic, liquid-phase markers should be 
nonabsorbable and should not adhere to either the GIT or 
solid food particles (198). Solid markers require 
efficient binding of the radiolabel throughout the period 
of study. Early studies incoporated the radionuclide 
into food (199), but since then a number of 
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absorbed onto a suspension of zirconium phosphate (200), 
l13mln-labelled d" th 1 t"" t " "d (DTPA) le y ene rlamlnepen aacetlc aCl 
(201) and l31I-labelled human serum albumin (202). 
Radiopharmaceuticals labelled with technetium-99m are 
probably the most widely used, due to the advantages of 
the isotope. These radiopharmaceuticals include 
9 9 ~ c - l a b e l l e d d chelating agents (eg. DTPA (203), EDTA 
(204»; colloids (eg. sulphur colloid (205»; cells and 
blood elements (eg. erythrocytes (206», human serum 
albumin (207); polystyrene resins (208); and cellulose 
macromolecules (209). For an excellent discussion of 
99mTC-labelled radiopharmaceuticals, the reader is 
directed to the review by Eckelman and Levenson (210). 
For studies on the GI transit of dosage forms, the 
radiolabelled marker is either incorporated into the 
formulation or the marker is used to mimic the behaviour 
of the dosage form. Conventional methods of labelling 
require the marker to be incoporated as late as possible, 
thus reducing the risk of radioactive contamination 
during manufacture. This has caused problems with 
enteric-coated formulations. Recently, however, Parr et 
al (211) described a process to irradiate enteric-coated 
tablets, containing a small quantity of stable erbium 
isotope, in a neutron flux, to produce radioactive 
tablets containing erbium-171. 
1.4.3.3 Errors and corrections 
-47-
The technique of gamma scintigraphy, like many other 
scientific methods, has a number of inherent errors. 
These errors are related either to the physical 
properties of the radionuclides and instruments or to 
changes in the distribution of the radionuclide within 
the subject, and can be overcome by applying a number of 
suitable corrections. Physical corrections include those 
for radionuclide decay, septal penetration and scatter 
from high energy gamma rays. 
All radiation detectors will record some activity 
without a source present. This background activity is 
caused by radiation from natural radio-isotopes and 
cosmic rays, and by instrument noise. A simple 
subtraction of the background count from the gross count 
of the source will give the net count due to the source 
alone (192). 
Gastrointestinal transit studies often extend for 
many hours, and thus accurate results will require 
correction for radioactive decay (212). 
Modern gamma camera systems allow the activity from 
two isotopes to be measured concurrently. This property 
has been used to simultaneously measure the gastric 
emptying of liquid and solid components of a meal, using 
l13mln_OTPA as the liquid phase marker and paper 
impregnated with 9 9 ~ c - I a b e l l e d d sulphur colloid as the 
solid phase marker (213). However, an appropriate 
correction for the scatter down from the higher energy 
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isotope into the lower energy isotope window is required 
to give meaningful results. This is usually done by 
administering the high energy isotope first and measuring 
the counts in the low energy window. This value is then 
used as factor to correct the low energy counts obtained 
after administration of the second isotope. 
The use of high energy emitters, such as ll3m1n , 
also requires a correction for septal penetration of the 
collimator, using an empirically derived expression 
(214). The use of a collimator with septa of appropriate 
thickness will help reduce the errors due to septal 
penetration. 
Radiation from ingested isotopes will be scattered 
or absorbed by intervening tissues and bone, before 
reaching the gamma camera, causing the registered 
radiation to be attenuated (215). Attenuation is more 
pronounced when measuring gastric emptying, due to the 
anterior movement of the radiopharmaceutical as it 
descends from the fundus into the antrum. This movement 
results in an increase in anterior counts due to 
decreased tissue attenuation. Tothill et al (216) solved 
this problem by using a double-headed scanner to obtain 
anterior and posterior counts, from which they calculated 
the geometric mean of the counts, (anterior counts x 
posterior counts)l/2. A plot of the corrected counts 
against time produced a more representative emptying 
profile. Christian et al (217) later confirmed these 
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findings using a conventional gamma camera. Moore et al 
(218) noticed that liquids showed only a slight 
difference between anterior only counts and geometric 
mean counts, whereas the difference was more pronounced 
with solids. This was attributed to the greater 
attenuation of the low energy of technetium-99m, used as 
the solid phase marker, compared to the high energy of 
indium-Ill, used as the liquid phase marker. Harding et 
al (219) have, however, suggested that errors in 
measuring gastric emptying using gamma scintigtraphy are 
insignificant. Nevertheless, the geometric mean 
correction is routinely used in gastric emptying studies, 
and has also been validated for whole bowel transit 
(220). 
Two other methods of correcting for changes in the 
depth of source and attenuation have been suggested. The 
first requires anterior peak and anterior scatter counts, 
from which a peak-to-scatter ratio (P:S) is obtained 
(221). This ratio is then used to correct the anterior 
gastric counts and provides a convenient alternative to 
the geometric mean method. The second method uses a 
lateral image of the stomach to generate correction 
factors for posterior only images (222). It was argued 
that the lateral image method is a practical alternative, 
since the geometric mean correction is cumbersome and the 
P:S method is not suitable when using technetium, 
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Other cornmon errors with gamma scintigraphy include 
the distance of the subject from the collimator (191), 
the change in the position of the stomach during emptying 
(223) and patient motion during imaging (224). 
1.4.3.4 Evaluation of oral dosage forms using gamma 
scintigraphy 
Gamma scintigraphy has been extensively used to 
evaluate gastric emptying for clinical purposes (225). 
Its application for the evaluation of dosage forms in 
vivo has, in comparison, been a recent event. 
Extensive reviews of the potential of gamma 
scintigraphy as a tool in the assessment of radiolabelled 
drug formulations have been presented by Hardy and Wilson 
(226) and Wilson et al (227). The technique has been 
used to investigate rectal administration (228), nasal 
administration (229), parenteral administration (230), 
tumour targeting (231), tissue uptake and clearance of 
particles (232), and ocular administration (233). 
However, it is the application of the technique to 
investigate the GI fate of oral dosage forms that most 
concerns this discussion. 
The effect of eating and drinking on the buccal 
release of a model material, 9 9 ~ c - D T P A , , from a matrix 
tablet was measured using the gamma camera (234). Other 
studies have followed the oesophageal transit of capsules 
and concluded that capsules are best taken in an upright 
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position. A preliminary sip of water ensures the capsule 
does not remain in the oesophagus (235, 236). 
The disintegration of hard gelatin capsules in the 
stomach of fasting and non-fasting subjects was reported 
on by Hunter et al (237). Another study used the 
9 9 ~ c - D T P A A model to assess the in vivo dissolution rate 
of a sustained release tablet (238). A good correlation 
was obtained between the in vitro and in vivo release 
profiles. Beihn and Digenis (239) have proposed the use 
of perturbed angular correlation (PAC) as an alternative 
technique to measure the dissolution in vivo of the water 
soluble component of a solid dosage form. It is known 
that some radionuclides decay by emitting two gamma rays, 
with a unique time delay between the first and second 
emission, eg. indium-Ill. PAC involves the time-delayed 
coincidence counting of two cascading gamma rays that 
exhibit angular correlation. This angular correlation 
can be perturbed as a result of interactions between the 
excited nucleus and its environment, such as occurs 
during a phase change (solid to liquid), and the degree 
of perturbation is measured. A modification of this 
method, known as the summation peak ratio method, 
provided reliable dissolution data of tablets (240). 
This method has the advantage of requiring only one 
camera, as opposed to the three detectors required by 
PAC. Detailed images of the dissolution in vivo of 
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tablets can be achieved using a gamma camera fitted with 
a four pinhole collimator (241). 
It is not only the gastric performance of solid 
doses that have been evaluated. Liquid preparations, 
such as antacids, have also been evaluated (242). The 
gastric emptying of oils and liquid paraffin has been 
examined in rats (243). Both the type and volume of the 
oil altered the rate of gastric emptying. 
Gamma scintigraphy has become a potent tool to 
investigate the total GI transit of dosage forms. 
Studies have been conducted in both animals (244) and man 
(245). The influence of factors such as food (246), 
posture (247) and exercise (248) on the GI transit of 
pellet formulations has been investigated. Single-unit 
formulations have also been evaluated (249). 
The dual i s ~ t o p e e facility has enabled the GI transit 
of a pellet system and osmotic device to be monitored 
simultaneously in the same subject (250). The effect of 
food on the gastric emptying of each formulation was 
measured, as well as the release of material from the 
osmotic device. A similar dual isotope study has been 
conducted on the soluble and insoluble components of a 
capsule formulation (251). 
Scintigraphic studies have recently been coupled 
with pharmacokinetic studies. This combination of 
techniques allows the position of the formulation in vivo 
to be related to plasma and urine drug levels (252). The 
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influence of food on the disintegration/dispersion and 
transit of the dose form can also be related to the 
pharmacokinetic data (253). 
It should be remembered, that most of the above 
studies have been conducted in healthy subjects and thus, 
their clinical relevance is slightly circumspect. 
Recently conducted studies evaluating dosage forms in 
patients, have shown a significant difference in transit 
times between patients and healthy subjects (254). 
Informative reviews on the use of gamma scintigraphy 
to investigate the behaviour of oral dosage forms have 
been produced by Davis (255) and by Fell and Digenis 
(256). 
In conclusion, the technique of gamma scintigraphy 
has a number of distinct advantages over other methods to 
investigate the GI transit of oral dosage forms: 
i. it is a non-invasive technique; 
ii. the radiation dose is low; 
iii. there is no discomfort to the subjects; 
iv. easy labelling of formulations, using readily 
available isotopes; 
v. the transit of the actual dosage form is 
followed; 
vi. data can be quantified and obtained on a 
continuous basis; 
vii. two formulations can be monitored 
simultaneously. 
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The technique has the disadvantage of producing images 
which do not possess the same structural details as 
X-rays, but probably the major disadvantage is the cost 
of the instrument. 
1.5 The Gastrointestinal Barrier 
Oral drug administration has historically been the 
predominant route of drug delivery. An accurate control 
of drug bioavailability is necessary in order to optimise 
this delivery, which, in turn, requires knowledge of both 
the interactions of the drug with the components of the 
gut and the performance of the dosage form in controlling 
these interactions (257). 
In this section I shall explain why an understanding 
of GIT physiology, illustrated by considering drug 
absorption, and the GI transit of dosage forms, is 
important to the future design of oral coos. 
1.5.1 Drug Absorption 
The principal site of drug absorption is the small 
intestine (258). Absorption is facilitated by the large 
surface area created by surface folds at the macroscopic, 
microscopic and sub-microscopic levels: Kerckring folds, 
villi and microvilli (259). Some drugs are absorbed 
throughout the length of the small intestine, whereas 
others (eg. riboflavin (260» are absorbed only at 
• 
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specific sites, "absorption windows", usually in the 
jejunum (261). Both the impermeability to small 
hydrophilic molecules and low surface area of the 
stomach, and similarly the small absorptive area of the 
colon, make them unlikely routes of absorption (262). 
1.5.1.1 Mechanisms of absorption 
Drug molecules are transported across the 
semipermeable GI mucosa by one or more of the following 
mechanisms: 
i. Passive diffusion (263). Most lipid soluble 
drugs are absorbed by simple diffusion. The rate of 
absorption is influenced by changes in pH, an observation 
which led to the classical pH-partition hypothesis (264). 
Several problems arise in the quantitative application of 
this hypothesis (265). These include the variability in 
pH of the stomach, which could affect drug dissolution, 
and the pattern of water flow in the small intestine. 
ii. Pore transport (266). Small molecules (eg. 
urea) can diffuse through the pores associated with 
biological membranes. 
iii. Active transport (267). Drug molecules are 
transported across the membrane, against a concentration 
gradient, by a carrier substance. The mechanism is 
saturable, shows specificity, requires a source of 
energy, is often site specific, and can be inhibited • 
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iv. Facilitated transport (268). This is similar 
to active transport, but does not occur against a 
concentration gradient. 
v. Pinocytosis (159). Substrate particles are 
enveloped in vacuoles formed by the invagination of the 
apical cell membrane. 
1.5.1.2 Physiological factors affecting absorption 
The duration of absorption and of excretion will 
influence the duration of efficacy of a drug (269). The 
former cannot be longer than the residence time of the 
dosage form in the region of absorption. This residence 
time is itself dependent on the rate of gastric emptying 
of the formulation (270), and so, gastric emptying rather 
than permeation is prospectively the primary 
rate-limiting step in drug absorption (258). Thus, 
factors that affect gastric emptying (Section 1.2.1.2) 
could markedly influence drug absorption. 
The intake of food exerts a complex influence on 
bioavailability (271), by either enhancing 
bioavailability (eg. propranolol (272» or reducing 
bioavailability (eg. rifampicin (273». In other cases, 
the rate but not the extent of absorption is reduced (eg. 
paracetamol (274». These results are often due to the 
influence of food on processes such as GI motility, and 
first-pass metabolism (275). Furthermore, changes in the 
boundary conditions of the gut (276), such as pH, 
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temperature and osmolality, as a result of food intake, 
could also affect the mechanism of drug release, drug 
absorption and the performance of the dosage form (277). 
Other physiological factors that affect drug 
absorption include, administration of the dose at 
different phases of the MMC (278), disease states (279), 
and patient variability (eg. age) (275). 
1.5.1.3 Pharmaceutical factors affecting absorption 
Pharmaceutical variables that exert an effect on 
drug absorption include the nature of the dosage form, 
the drug itself, and formulation variables (280). 
Bogentoft et al (281) demonstrated that the absorption of 
aspirin from enteric-coated granules was not influenced 
by food, whereas a corresponding tablet formulation gave 
lower plasma concentrations. Similarly, the 
inter-subject variation in plasma concentration was less 
for a granule formulation of aspirin, than for a tablet 
product (282). Drugs that either reduce (eg. atropine) 
or increase (eg. metoclopramide) gastric motility will 
affect absorption of co-administered drugs. Similarly, 
drugs affecting mesenteric blood flow, (eg. nifedipine) 
will influence the absorption rate of a second drug 
(283). Furthermore, the concomitant administration of a 
second formulation (eg. antacids) can reduce drug 
bioavailability (284). Formulation excipients, such as 
the vehicle, can also affect bioavailability. Soci and 
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Parrott (285) found that the absorption of nitrofurantoin 
from various suspensions was dependent on the vehicle. 
Algin, and guar gum suspensions exhibited delayed 
absorption compared to aqueous suspensions. 
1.5.2 Gastrointestinal Transit of Solid Doses 
The duration of drug absorption is partially 
governed by the GI transit of the formulation. It can be 
envisaged, that factors influencing GI motility (Section 
1.2) will have a bearing on the transit of solid doses. 
It is also recognised, that the nature of the 
formulation, single-unit or multiple-unit, will determine 
its GI transit (146). 
1.5.2.1 Gastric emptying 
Oral doses administered to a fed stomach have an 
emptying pattern similar to food. Thus, liquid 
formulations behave as simple liquids, and show an 
exponential emptying pattern (286). The drug solution 
from disintegrating solid doses will have a similar 
exponential pattern of emptying, after an initial 
dissolution lag phase (287). 
Multiple-unit formulations, composed of sub-units 
small enough to pass through the constricted pylorus, 
will exhibit a disintegration lag phase, followed by 
gradual emptying of the sub-units (288). Gradual 
emptying ensures the sub-units are dispersed along the 
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length of the small intestine (289), resulting in lower 
local drug concentrations, and reduced irritation of the 
intestinal mucosa (290). The initial gastric dispersion 
of the sub-units is, however, dependent on the 
physiological condition of the stomach. Dispersion 
occurs readily after a meal with a high liquid content, 
but is limited after administration to a fasting stomach 
(237). The lack of dispersion results in the bolus 
emptying of material, which has been observed with both 
encapsulated powders (237) and pellets (291). O'Reilly 
et al (292), recently demonstrated a linear emptying 
pattern for sub-units when the multiple-unit formulation 
was taken either with or after a meal, but an exponential 
pattern when taken before a meal. However, emptying 
half-times of 3-4h, similar to those reported by 
Bechgaard and Christensen (147), were observed for all 
the dosing regimes. Hunter et al (293) have rationalised 
the various emptying patterns observed with capsule 
formulations into five main types, described by the 
pattern of the gastric emptying profile. 
Investigations into the effect of particle density 
on the GI transit of multiple-unit systems have produced 
conflicting results. An initial study in ileostomy 
subjects, suggested heavy pellets had a slower transit 
time than light pellets (175). A later study, in healthy 
subjects, could not confirm this effect of density (294). 
Christensen et al (295) have reported that light pellets 
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float in the proximal stomach of healthy subjects, 
resulting in a longer lag phase before emptying than for 
heavy pellets. However, the half-times for emptying were 
similar for both types of pellets. In contrast a second 
study in ileostomy subjects, reported analogous patterns 
of emptying for both heavy and light pellets (296). In 
both studies, the intestinal transit of the pellets was 
not affected by particle density. An interesting 
observation, with possible clinical consequences, 
reported that fed subjects exposed to noise-induced 
stress exhibited a faster gastric emptying of capsule 
contents than those not exposed to the stress (297). 
Single-unit, non-disintegrating formulations behave 
like large indigestible solids, and are emptied by phase 
3 activity of the MMC (298). Park et al (249) report 
that e n t e r i c - c o a ~ e d d tablets empty erratically from the 
fasted stomach, depending on their time of arrival in the 
stomach in relation to the occurence of MMC contractions. 
Emptying was independent of the size, shape and volume of 
the tablets. A high inter- and intra-subject variation 
in transit time, attributed to erratic gastric emptying, 
has also been observed in fed ileostomy subjects (299). 
Studies on the effect of density have shown tablets of 
low density to float on top of gastric contents, whereas 
more dense tablets sink to the distal stomach (300). 
Thus, the intake of food, and especially the energy 
content of the meal, will exert a greater influence on 
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the gastric emptying of single-units than the emptying of 
multiple-unit systems (301). Therefore, the high 
inter-subject variation observed in the gastric emptying 
of single-units must be considered when designing new CR 
formulations (302). 
1.5.2.2 Intestinal transit 
There have been few studies in the past on the 
intestinal transit of dosage forms, largely due to the 
lack of suitable measuring techniques. An early study by 
Rosswick et al (303), found the intestinal transit of a 
capsule to range between 1.5-16h, with a mean value of 
about 4h. 
Recent extensive use of gamma scintigraphy to 
investigate the GI behaviour of pharmaceuticals, has 
produced an abundance of suitable data. Davis et al 
(304) have produced a comprehensive report describing the 
intestinal transit of solutions, pellets and 
single-units. They determined a mean transit time of 
about three hours, which was independent of the dosage 
form and fed state. This result is in agreement with 
Malagelada et al ·(305), who reported transit times of 
about three hours for both solids and solutions. Studies 
by Kaus (306), investigating the rate of transit of a 
non-disintegrating unit, have also shown intestinal 
transit to be less variable than gastric emptying. 
Passage through the duodenum was rapid, followed by a 
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mean transit rate of 4.2-S.6cm/min. This correlates well 
with the value of 4.7cm/min for the velocity of travel of 
the MMC down the intestine (307). Exercise has been 
shown to have no affect on the intestinal transit of a 
pellet formulation in healthy subjects (248). 
1.5.2.3 Colonic transit 
The predictable nature of intestinal transit has 
generated enthusiasm to investigate the suitability of 
oral administration, rather than rectal, for the local 
release of drug. Localised systems have the advantage of 
reduced side-effects and the delivery of effective 
concentrations of drug to the appropriate site. Commonly 
used rectal preparations, such as enemas, do not spread 
regularly within the colon (308), and often fail to reach 
the transverse colon (309). Efforts in research have 
been directed to the oral delivery of drugs, such as 
5-aminosalicylic acid (S-ASA), to the colon, without loss 
of drug in the small intestine. A number of coated 
systems have been developed (310, 311), with varying 
degrees of success. Other systems rely on the enzymatic 
activity of bacterial flora in the colon. For example, a 
polymeric drug has been developed, which is reduced by 
bacterial enzymes to S-ASA (312). The molecular size of 
the polymer precludes intestinal absorption. 
These systems, whilst being technically efficient, 
could be further improved by considering the transit 
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characteristics of dosage forms, especially in the colon. 
The knowledge that multiple-units become widely dispersed 
within the colon (313), led to the development of 
multiple-unit systems for the delivery of 5-ASA to the 
colon (314). Hardy et al (315) have suggested that the 
extent of dispersal is size dependent, since large 
particles pass through the colon more rapidly than 
smaller particles. Furthermore, their results indicate 
that a timed release formulation should retain drug 
within the preparation for about five hours after 
administration to a fasted patient. This would allow 
time for gastric emptying and intestinal transit. Drug 
released over the next ten hours from a dispersive 
formulation, would distribute throughout the ascending 
and transverse colon. 
1.5.3 Oral Controlled Drug Delivery Systems 
The physicochemical characteristics of the drug, the 
nature of the delivery system, and the GI transit of the 
dosage form are criteria that must be considered during 
formulation. Davis (316) has framed this into the 
concept of the trinity of drug, dosage form, and 
destination. Theoretical models, which consider the 
complex GI environment and formulation variables, are now 
being used in the rational design of oral COOS (317). 
Davis et al have developed (318), and validated (319), a 
computer simulation, that uses preformulation data, 
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permeability values and estimates of physiological 
variables, for the formulation of delivery systems. A 
similar model approach, developed by Ho et al (320), 
introduces the concept of the anatomical reserve length, 
described as the length of small intestine yet available 
for absorption: 
where 
* RL = L - I 
RL = anatomical reserve length, cm 
L = maximum theoretical reserve length, ie. the length 
of the human small intestine, 300-350cm 
* I = length at which absorption is completed, cm. 
Thus, the reserve length of a soluble drug will be larger 
than that of a poorly soluble drug. In their discussion, 
the authors stress the necessary quantitative 
interrelationship of physiological, physicochemical, and 
pharmaceutical parameters, within the framework of the 
reserve length, in the development of drug delivery 
systems. Several examples were provided to support the 
use of the model. 
Currently available CR products boast zero-order 
release over twelve hours or more. These claims have 
little meaning, unless the drug is extensively absorbed 
in the colon, considering the potentially short stomach 
to caecum transit time in the fasted state. This could 
result in a reduced systemic level of drug, and a 
significant fraction of the dose being wasted. Thus, the 
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future development of CR systems should concentrate on 
prolonging the GI residence of the dosage form (321), as 
well as optimising drug release rates. Gastric emptying 
of dosage forms is variable and influenced by factors 
such as diet and the type of dosage form (322). 
Conversely small intestine transit appears to be regular 
and unaffected by these factors (304). Control of the 
gastric emptying of dosage forms is, therefore, the 
preferred option. 
A number of pharmaceutical strategies, such as 
particle size (323) and particle density (290), have been 
proposed to control gastric emptying. Devices which 
float on the gastric contents have been developed (324). 
These systems are either of low density or are rendered 
buoyant by the liberation of gas into a deformable hollow 
membrane (325). 'A recent innovation has even maintained 
buoyancy in the fasted state (326). The suitability of 
such systems for prolonging gastric residence is not 
entirely conclusive (327, 328). Another approach is the 
use of bioadhesives which adhere to the mucin/epithelial 
surface of the GIT, to provide a localised platform for 
drug release (329). The use of fatty acids to delay 
gastric emptying and improve drug bioavailability has 
been demonstrated in both humans (330) and rats (331). 
Apart from the transit of COOS, future designs 
should consider the boundary conditions of the gut, in 
particular the variations in GI pH. Bechgaard and 
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Saggesen (332) found lower intra-subject variations in 
the availability of propoxyphene from a pH-independent 
multiple-unit system, than from a pH-dependent system. 
Despite this, Sechgaard et al (333) have developed an 
alkaline pH-dependent pellet formulation of indomethacin. 
Drug release occurs only in the lower regions of the 
intestine, and drug availability is independent of 
gastric activity (334). A theophylline product 
consisting of pellets compressed within a slowly 
disintegrating tablet matrix, has managed to combine the 
elements relating to single- and multiple-units, is not 
pH sensitive and is unaffected by gastric activity (335). 
These examples suggest that the effects of GI 
physiological variables on the controlled delivery of 
drugs to the GIT, can be minimised by appropriate 
application of formulation procedures. A further 
understanding of these variables should lead to the 
development of more reliable dosage forms, and hence more 
effective drug therapy. 
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1.6 Thesis Objectives 
In the preceding pages I have attempted to 
illustrate the importance of considering both 
physiological and pharmaceutical criteria for the future 
design of oral coos. 
In this thesis I have identified two physiological 
parameters, and two pharmaceutical parameters which merit 
investigation: 
i. the influence of posture on the gastric 
emptying of pellets; 
ii. the influence of the time of day of 
administration on the GI transit of pellets; 
iii. the influence of the mucoadhesive, 
polycarbophil on the GI transit of pellets; 
iv. the GI ·transit of tablets, investigating, 
(a) the effect of tablet size, and 
(b) the influence of food. 
The conclusions generated from these investigations, 
and from future similar studies, should enable the design 
of oral coos which are not only technically elaborate, 
but also physiologically competent. 
CHAPTER TWO: 
THE INFLUENCE OF POSTURE 
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2.1 Introduction 
In this chapter I shall present the findings from an 
investigation to measure the gastric emptying in supine 
subjects, of a placebo pellet formulation. 
The rate of GE will determine the rate of absorption 
of many orally administered drugs, and factors 
influencing GE will, in turn, influence drug absorption 
(Section 1.5). One likely influence on GE is the 
posture, either supine or upright, of patients. Oral 
pharmaceuticals are often administered to patients 
confined to bed, and taken by patients prior to retiring 
for the night. Evidence suggests that GE patterns in 
supine patients who have undergone certain forms of 
surgery, differ from postoperative GE patterns in the 
upright posture (336,337). 
The stomach empties more rapidly in neonates lying 
either in the prone position or on their right sides, 
than when supine or on their left sides (338). However, 
no difference was seen in babies, for the same four 
positions (339). Hunt et a1 (39) reported that the GE of 
liquid test meals was slowed by tipping the subjects into 
a head down position. Naturally, this is an unreasonably 
severe posture, but a later study demonstrated the 
influence of the supine positon on the GE of simple 
liquids (340). Emptying was faster in subjects lying on 
the right side, than either on the left side or sitting. 
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Nimmo and Prescott (341) report a delay in 
paracetamol absorption in subjects lying on the left 
side. A similar affect on the absorption of aspirin 
solution in supine subjects was attributed to a delay in 
GE (342). Posture is known to affect the oesophageal 
transit of dosage forms (343), and there is some evidence 
that body position may alter the GE of pellets in hard 
gelatin capsules (288). A comparison of two different 
aminophylline and theophylline pellet formulations 
suggested differences in theophylline levels between the 
formulations could become clinically relevant in the 
supine position at night (344). 
Loo et al (345) report a slower GE of liver 
particles in supine subjects. They suggest a passive 
redistribution of the meal to the posteriorly located 
fundus, where no grinding activity is exerted on the 
food, causing a delay in GE. Thus, a combination of food 
and body position may have a marked affect on GE. 
The above studies have mainly considered the effect 
of posture on the GE of food. A study was, therefore, 
designed to investigate the influence of body posture on 
the GE of pellets in fasted and fed subjects. 
2.2 Materials and Methods 
2.2.1 Preparation of Formulations 
Beads of Arnberlite IRA4l0 (BOH), an anionic 
ion-exchange resin, were used as the placebo pellet 
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formulation. Ion-exchange resins need to be washed and 
regenerated before use, and the following standard 
procedure was used (346): 
i. soak resin in 2N sodium hydroxide (NaOH) 
solution for 20min: 
ii. recover the resin by filtration, and wash with 
water, methanol, and water again: 
iii. soak resin in 2N hydrochloric acid (HCl) for 
20min, recover and wash as above, 
iv. repeat steps i-iii twice: 
v. soak for 30min to regenerate resin, in 2N HCI 
for cationic exchangers, or 2N NaOH for 
anionic exchangers. 
Only pellets in the size range 0.5-1.0mm were used 
in the study. These were obtained by sieving about 50g 
resin in a typical nest of sieves, 10cm diameter sieves 
(Endecotts Test Sieves Ltd.), assembled in decreasing 
aperture size in a square root of two geometric 
progression. The sieves were agitated for 30min on a 
sieve shaker (EFLIMKI1, Endecotts Test Sieves Ltd), and 
the appropriate fraction collected. The density of the 
pellets was previously determined as 1.17g/cm3 using an 
air pycnometer (Model 930, Beckmann). 
The resin was labelled by soaking 6g in 10mi 
99mTc-sodium pertechnetate solution (CIS(UK) Ltd.) for 
10min. The resin was recovered and dried in a fan oven 
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at 70·C. The activity of the recovered resin was 
measured before and after drying. There was no 
difference between the values, implying drying did not 
disrupt the isotope binding. The tenacious nature of 
isotope binding to resins is well documented. 
Theodorakis et al (209) studied the binding of 
technetium-99m to a variety of polymer resins. They 
found that the isotope had a very stable binding in vitro 
to Dowex resin, another commercial resin similar to 
Amberlite resin. Copping (347) has tested the binding in 
vitro of technetium-99m to Amberlite IRA410 resin. 
Labelled resin was soaked in solutions, varying from pHI 
to pH14. A maximum of 1.8% of the isotope leached out 
over a 2h period. On the basis of these results, only a 
simple binding test was performed on the labelled pellets 
in this study. About SOOmg of labelled resin was added 
to two separate beakers containing lOamI O.lN Hel, and 
lOOml O.lN NaOH. A magnetic stirrer and "flea" were used 
to stir the contents of the beakers. A lOml aliquot was 
taken from each beaker after 2h, and activity measured in 
a gamma counter (Intertechnique CG4000). The activity 
detected was negligible, and the binding was considered 
to be stable. 
Stability in vitro does not a posteriori imply a 
stable binding in vivo. 99mTc-pertechnetate is readily 
absorbed from the small intestine, and accumulates in the 
thyroid and bladder (348). Thus, if the isotope leached 
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from the resin, some activity would be detected in these 
organs. A check of the thyroid region was made during 
the study to ensure no isotope had been lost from the 
resin. 
The labelled pellets were filled into size 0 hard 
gelatin capsules (Capsugel), to a notional fill weight of 
310mg. The capsules had a disintegration time of less 
than 10min in O.lM HCl, as measured by the standard BP 
test (349). Each filled capsule had an activity of 3MBq 
technetium-99m at the time of administration. The total 
radiation absorbed was estimated as O.603mG/MBq for the 
stomach and small intestine, and 0.045mG/MBq for the 
whole body (133,350). 
2.2.2 In-vivo Study 
The study was approved by the Ethical Committee of 
the University of Nottingham, and conducted in accordance 
with the declaration of Helsinki Guidelines for Ethics in 
Research. Approval to administer radiopharmaceuticals 
was obtained from the Department of Health and Social 
Security (DHSS). The investigation was performed in two 
separate stages. The first part was conducted in fasting 
subjects, and the second part in fed subjects. 
The first study involved six male subjects (age 
18-25, height 1.7-2.0m, weight 65-75kg), who were 
non-smokers, were not on any medication, had abstained 
from alcohol for 24h, and had fasted for lOh before the 
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study. On the morning of the study, each subject 
swallowed one capsule with 100mi water, and then lay face 
upwards on stretcher trolleys. The subjects remained 
supine for the duration of the study (4h) and were only 
allowed to leave the trolley when they needed to urinate. 
They were asked to keep all body movements to a minimum 
during the study. Anatomical markers, containing O.lMBq 
technetium-99m, were taped to the skin, anteriorly and 
posteriorly, over the liver and to the right of the 
stomach. 
Anterior and posterior images, each of 60s duration, 
were taken at regular intervals, using a gamma camera 
(General Electric Maxicamera, Type II) having a 40cm 
field of view. Since only technetium-99m was being used, 
the camera was fitted with a low energy (160keV) 
parallel-hole collimator. Posterior images were recorded 
after the subjects had rolled over onto their fronts. 
Images were recorded on a computer (Nodecrest), and 
stored on magnetic tape for subsequent analysis. 
The images were analysed on the computer, by drawing 
regions of interest (ROI), using an electric cursor, 
around the position of the stomach. The position of the 
stomach in each successive image, in relation to the 
external marker, was determined by referring to the 
preceding images. A second ROI was drawn on each image, 
away from the main area of activity, to assess the 
background counts. The appropriate computer software 
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enabled the activity in each stomach region to be 
quantified, corrected for background activity and 
radioactive decay. The error due to the variation in 
depth was also corrected on the computer, using the 
geometric mean of corresponding anterior and posterior 
views (216). The resultant corrected %activity was then 
plotted against time. 
A control study was conducted a week later, with the 
subjects remaining in an upright position during and 
between imaging. 
The fed study was conducted in the same manner about 
twelve months later. A further five male subjects 
participated (age 18-25, height 1.6-2.0m, weight 60-75kg) 
under the same constraints as described above. However, 
in this study, the subjects consumed a light breakfast 
(1800kJ) consisiting of: 
2 slices toast 
bowl of cereal 
butter and marmalade 
120ml milk 
lOOml orange juice 
about 15rnin before taking the encapsulated pellets. The 
duration of this study was 7h. A similar control study 
was conducted one week later, with the subjects in the 
upright posture. 
In neither the fed nor the fasted investigation did 
the subjects complain of any untoward side-effects. 
2.3 Results and Discussion 
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2.3.1 Fasted Study 
Gastric emptying data have been expressed as the 
time for 50% of the activity to leave the stomach 
(St50%). The results of the investigation are detailed 
in Tables 2.1-2.3. Gastric emptying profiles for the 
supine and control studies are shown in Figures 2.1-2.3, 
and representative scintiscans are presented in Figures 
2.4 and 2.5. 
The pellets were released rapidly from the hard 
gelatin capsule, and the dispersion of the pellets 
enabled ready identification of the stomach region for 
subsequent creation of ROI. The scintiscans show the 
unreleased pellets, the pellets dispersing in the 
stomach, and gastric emptying of the pellets. An outline 
of the stomach, and in later chapters of the colon, has 
been drawn around' the pellets to improve visualisation of 
the images. The anatomical marker is also visible. 
Gastric emptying of the pellets generally began 
within 20min, the time between the first and second 
images. Subject 4 exhibited a distinct lag phase before 
emptying commenced, in both the supine and control study 
(Figure 2.1). The mean emptying profiles (Figure 2.2) 
indicate that the pellets empty in an exponential manner, 
in both the supine and control study. However, some 
individuals exhibited an almost bolus emptying of the 
pellets, as illustrated by Figure 2.1. This rapid 
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emptying as a whole has been previously described by 
Hunter et al (288). 
A paired Student t test on the St50% values, 
suggests there is no significant difference (p>O.l) 
between the supine and upright postures. Few studies of 
this nature have been conducted, and thus comparison with 
previous results is difficult. Nevertheless, the mean 
St50% (=s.e.m.) for the supine study, 32 (12)min, and for 
the control study, 52 (l6)min, are in close agreement 
with a previous investigation. Hardy and Perkins (220) 
report a gastric emptying t50% of 45min (n=4) for pellets 
given to fasted subjects in the upright position. Sutton 
et al (180) conducted a study to compare the GE, in 
supine subjects, of orange flavoured water, measured 
either by the technique of epigastric impedance or gamma 
scintigraphy. A 'mean GE t50% value of 26min was recorded 
using the impedance method, and 27min using gamma 
scintigraphy (n=5). 
The rapid emptying observed in my investigation can 
be ascribed to the contractions of the MMC. 
Administration of the encapsulated pellets during either 
phase 2 or phase 3 contractions would result in the rapid 
emptying of the pellets. However, administration during 
phase 1 of the MMC, when there are no contractions, would 
result in a slower emptying, with a possible lag phase 
during which the pellets passively disperse in the 
stomach. This would explain the lag phase exhibited by 
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subject 4. Naturally, the subjects would be in different 
phases of the MMC prior to administration of the capsule, 
hence the marginally different rates of emptying and the 
relatively large s.e.m. values on the mean emptying 
profiles (Figure 2.2). 
Subject 6 inadvertently consumed a bowl of cereal on 
the morning of the supine study, and thus has not been 
included in the mean values. To allow comparison with 
the control study, he consumed the same volume of food 
before taking the capsule on the upright study day. In 
both cases he shows a distinct lag phase before GE. The 
GE profiles for subject 6 (Figure 2.3) are also different 
from the profiles illustrated in Figures 2.1-2.2, 
exhibiting a more gradual pattern of emptying. 
2.3.2 Fed Study 
Gastric emptying data and profiles are presented in 
Tables 2.4-2.6 and Figures 2.6 and 2.9, and 
representative scintiscans in Figures 2.7. 
Dispersion of the pellets again enabled the stomach 
region to be readily identified. The subjects all 
exhibited a lag phase before GE began, in both the supine 
and control study. The pellets exhibited an almost 
linear pattern of GE, after the lag phase. This linear 
profile is the characteristic emptying pattern of solid 
food (216), and indicates that the pellets become mixed 
with the food before emptying commences (292). A paired 
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Student t test on the St50% values indicates there is no 
significant difference (p>O.5) between the supine and 
upright positions. The mean StsO% (=s.e.m.) value of 191 
(25)min for the supine study, and 175 (21)min for the 
control study are similar in magnitude to previous 
investigations. Davis (322) reports mean GE t50% values 
of 115 (16)min after a light breakfast, and 225 (38)min 
after a heavy breakfast. Tiaprofenic acid pellets 
exhibited a more rapid emptying, with mean GE tsO% values 
of 77min after a light breakfast, and 170min after a 
heavy breakfast (246). 
2.3.3 Supine vs Upright, Fed vs Fasted 
In both the fed and fasted investigations, there is 
no significant difference between the supine St50% values 
and the upright StSO% values. A similar finding was 
reported by Mannell and Esser (351), who investigated the 
GE of a solid meal in supine and erect subjects. Bennett 
et al (352) investigated the influence of posture on the 
GE of antacids. They noticed that the GE of alginate 
antacids was faster in subjects lying on their left 
sides, and slowest in subjects lying on their right 
sides. More importantly, the emptying, in the supine 
position, of a liquid meal administered with the 
antacids, was similar to that measured in subjects in an 
upright position. 
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A comparison of fed and fasted results illustrates 
the effect of food on GE. The mean GE data for both the 
fasted and fed investigations are illustrated in Figure 
2.8. An unpaired Student t test on the St50% values for 
both the supine studies, indicates there is a significant 
difference (p<O.OOl) between the fed and fasted values. 
Similarly a significant difference (p<O.Ol) was found 
between the fed upright and fasted upright values. The 
influence of food on GE has been illustrated by Davis 
(322). As mentioned above (Section 2.3.2), in that 
study, GE was emptying was slower after a heavy breakfast 
than after a light breakfast. 
An understanding of two physiological processes 
helps to explain the effect of food on GE. Firstly, the 
almost bolus emptying of the pellets in the fasted state 
can be related to the contractions of the MMe, as 
described above (Section 2.3.1). These contractions are 
not present in the fed state, resulting in a slower 
emptying. 
Secondly, in the fed state, a lag phase before 
emptying begins is commonly observed. This reflects a 
redistribution of food from the quiet fundus to the 
active antrum, and the preparation of solid food into 
chyme before emptying can commence (353). Pellets 
initially remain in the upper half of the stomach, 
dispersed in the food (292), and then become dispersed 
throughout the stomach (237), presumably as the food 
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redistributes. The apparent lag phase before GE in the 
fed study is a consequence of these processes. The 
subsequent activity in the antrum would then cause the 
emptying of these small pellets. The GE of indigestible 
particles is further discussed in Chapter 5. 
Subject 1 participated in both the fed and fasted 
investigations, and a comparison of the emptying profiles 
(Figure 2.9) illustrates the influence of food on GE. 
The pronounced lag phase in the fed supine study is 
probably a consequence not only of the above described 
processes, but may reflect the passive redistribution of 
food from the antrum back to the quiet fundus, as 
described by Loo et al (345). 
In contrast to my findings, Kaus et al (25l) did not 
observe a difference between the emptying rates of the 
soluble and i n s o ~ u b l e e components of a formulation in 
fasting and fed supine subjects. One possible 
explanation for this difference, is the proportionally 
larger volume of liquid ingested by the subjects in that 
study. Hunter et al (293) suggest the dispersion of 
capsule contents occurs more rapidly with meals of high 
liquid content. This would result in a faster rate of 
emptying in the fed state, akin to the rate in the fasted 
state. 
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2.4 Conclusions 
The following conclusions can be drawn from the 
results of this investigation: 
i. The gastric emptying of pellets is not 
influenced by the supine position in either 
the fasted or fed state. 
ii. Gastric emptying of pellets is slower in the 
fed state, in both the supine and upright 
posture. 
iii. In the fed state, pellets empty predictably 
and gradually, after an initial lag phase. 
iv. Pellets empty rapidly and less predictably, in 
the fasted state. 
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Table 2.1 Gastric emEtling data for the fasted 
sUEine studl %activitl remaining in the 
stomach. 
Subject 1 2 3 4 5 mean s.e.m. 
Time (min) 
0 100 100 100 100 100 100 
20 49 35 73 100 37 59 11 
60 12 a a 91 7 22 16 
80 11 0 0 58 0 14 10 
120 8 0 0 2 0 2 
140 5 0 0 0 0 1 
160 0 0 0 0 0 0 
Table 2.2 Gastric emEtying data for the fasted 
control study - % a c t i v i t ~ ~ remaining in the 
stomach. 
Subject 1 2 3 4 5 mean s.e.m. 
Time (min) 
a 100 100 100 100 100 100 
20 63 95 37 100 100 79 13 
35 48 0 0 100 100 50 20 
50 20 0 0 100 96 43 20 
60 a 0 0 100 60 32 18 
75 0 0 0 100 56 31 18 
90 0 0 0 100 52 30 18 
110 0 0 0 18 32 10 6 
125 0 0 a 0 0 0 
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Table 2.3 Lag time and Gastric emEtying (StSO%) 
values for the fasted sUQine and control 
studies. 
Supine study Control study 
Lag Time St50% Lag Time St50% 
(min) (min) (min) (min) 
Subject 
1 <5 20 <5 30 
2 <5 15 <5 25 
3 <5 25 <5 15 
4 40 85 90 100 
5 <5 15 35 90 
mean 32 52 
s.e.m. 12 16 
6 20 90 20 55 
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Table 2.4 Gastric e m Q t ~ i n g g data for the fed sUQine 
s t u d ~ ~ - % a c t i v i t ~ ~ remaining in the 
stomach. 
Subject 1 2 3 4 5 mean s.e.m. 
Time (min) 
a 100 100 100 100 100 100 
15 100 100 100 100 100 100 
30 100 100 100 100 100 100 
45 100 83 87 90 100 92 3 
60 86 60 81 84 100 82 6 
75 80 53 81 81 100 79 7 
90 79 51 76 76 100 76 7 
105 76 48 71 76 100 74 7 
120 76 46 71 76 100 74 8 
150 71 44 66 76 82 72 7 
180 66 31 59 73 39 54 7 
210 60 9 49 71 22 42 10 
240 44 a 33 68 4 30 11 
270 41 a 22 27 a 20 8 
300 29 a 0 25 0 11 6 
330 a a a a a a 
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Table 2.5 Gastric emQtying data for the fed control 
study - %activity remaining in the 
stomach. 
Subject 1 2 3 4 5 mean s.e.m. 
Time (min) 
a 100 100 100 100 100 100 
15 100 100 100 100 100 100 
30 100 100 100 100 100 100 
45 100 100 100 100 100 100 
60 100 100 100 100 100 100 
75 76 100 100 100 100 95 4 
90 61 100 100 100 100 92 7 
105 43 90 100 100 100 87 10 
120 31 81 100 100 100 82 12 
150 15 65 78 88 81 67 12 
180 a 42 30 83 69 45 13 
210 a 26 16 66 22 26 10 
240 a 14 8 51 15 17 5 
270 a 14 a 36 11 12 6 
300 0 0 a 32 a 6 6 
330 0 a a 10 a 2 
360 0 a 0 0 0 a 
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Table 2.6 Lag time and Gastric emQtying (St50%) 
values for the fed sUQine and control 
studies. 
Supine study Control study 
Lag Time St50% Lag Time St50% 
(min) (min) (min) (min) 
Subject 
1 120 170 60 100 
2 30 95 90 170 
3 30 205 120 170 
4 30 255 120 245 
5 45 230 120 190 
mean 51 191 102 175 
s.e.m. 16 25 11 21 
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CHAPTER THREE: 
TIME OF DAY OF ADMINISTRATION 
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3.1 Introduction 
This chapter describes the findings of an 
investigation designed to determine the influence of the 
time of day of administration on the GI transit of a 
placebo pellet formulation. 
3.1.1 Chronobio!ogy 
The subject of chronobiology has markedly grown 
since the investigations, conducted in the l890s, into 
the relationship between mental efficiency and the time 
of day (354). A number of cyclic physiological and 
behaviourial processes have been identified, eg. rapid 
eye movement (REM) sleep (355), diurnal changes in body 
temperature (356), and the menstrual cycle. Attention 
has been recently directed to investigating physiological 
functions that exhibit ultradian cycles, ie. cycles that 
occur with a periodicity of about 90min (357). The REM 
sleep cycle is one example of an ultradian process, but 
others include urine flow (358) and alertness (359). 
Ultradian periodicity has been identified in the eating 
behaviour of both monkeys (360) and humans (361). 
However, the function most relevant to this discussion is 
the cyclic nature of GI contractions in the fasted state. 
As early as 1869, Legros and Onimus (362), noted the 
occurence of rhythmic contractions of the upper and lower 
segments of the 5I in dogs. In 1922, Wada (363) also 
demonstrated a rhythmicity, of about 100min, in gastric 
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activity. However, it was not until 1969, that 
Szursweski (63) rationalised this rhythmic activity, 
which occurs only in the fasted state, into what is now 
described as the MMC (Section 1.2.3). A burst of motor 
activity, with a periodicity of 90-l20min, originates in 
the gastroduodenal region and migrates distally to the 
terminal ileum. Control of the periodicity of the MMC 
has not been completely determined, although an 
oscillator located outside the gut has been proposed 
(87). The exact anatomic location of this oscillator has 
yet to be demonstrated, but an oscillatory mechanism 
within the central nervous 'system has been suggested 
(364). 
3.1.2 Chronopharmacology 
Another a r e ~ ~ of study that has attracted attention, 
is the topic of chronopharmacology. Tomlinson (365) has 
elucidated on the importance of timing of drug arrival at 
its receptor. The activity of some pharmacological 
agents depends on the circadian stage at which they are 
administered. This has been extensively demonstrated for 
cancer chemotherapy. Mice, inoculated with acute 
leukaemia, varied in their response to cytosine 
arabinoside, depending on the dosing schedule (366). 
There are several instances in the literature 
relating drug bioavailability with the time of day of 
administration (367). One drug that has been 
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investigated in this context is theophylline. Asthmatic 
children, receiving conventional theophylline 
preparations, have to be maintained on a 6h dosing 
regimen to sustain serum theophylline levels. An 
investigation into a SR formulation, designed for a twice 
daily regimen, noticed a circadian variation in 
theophylline pharmacokinetics (368). It was suggested 
that, this variation could be related to the fasting or 
fed state of the children. A temporal variation in 
theophylline pharmacokinetics, also from a twice daily SR 
formulation, was observed in adults (369). Serum levels 
were higher in the morning, than in the evening. Diurnal 
variation in the clinical features of manic-depressive 
illness has been widely studied (370). An improvement in 
response to therapy was achieved by correlating drug 
dosing regimens with these variations. 
The importance of GI transit on drug absorption has 
been previously discussed (Section 1.5). The importance 
of the time of day of administration on drug 
pharmacokinetics and response to therapy is illustrated 
by the examples cited above. This relationship between 
drug performance and the time of administration is 
possibly related to the GI transit of the dosage form. 
Of particular importance are the strong contractions 
during the fasted state, which may accelerate the transit 
of the dosage form. Thus, the advantage of reduced 
dosing regimens afforded with CR systems, could be 
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markedly affected by this contractile activity. It was, 
therefore, considered relevant to conduct an 
investigation into the effect of the time of day of 
administration on the GI transit of an oral formulation, 
during MMC activity. 
3.2 Materials and Methods 
3.2.1 Preparation of Formulations 
Amberlite lRA4l0 resin (BOH) beads were used as the 
placebo pellet formulation. The pellets were prepared, 
labelled with technetium-99m, and encapsulated as 
previously described (Section 2.2.1). Similar in vitro 
tests and an in vivo check confirmed the integrity of the 
isotope binding to the resin, and the rapid 
disintegration of the capsules. Each filled capsule had 
an activity of about 3MBq technetium-99m at the time of 
administration. The total radiation dose absorbed was 
estimated as 0.603mG/MBq for the stomach and small 
intestine, and 0.045mG/MBq for the whole body (133,350). 
3.2.2 In vivo Study 
The study was approved by the Ethical Committee of 
the University of Nottingham, and conducted in accordance 
with the declaration of Helsinki Guidelines for Ethics in 
Research. Approval to administer radiopharmaceuticals 
was obtained from the DHSS. 
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The investigation was conducted on three separate 
days. The morning study commenced at 8.l5a.m. on the 
first day; the afternoon study, six days later, commenced 
at 1.00p.m.: and the evening study, a further six days 
later, commenced at 6.00p.m. Five male subjects (age 
18-22, height 1.7-l.9m, weight 60-75kg), who were 
non-smokers, were not on any medication, had abstained 
from alcohol for 24h, and had fasted for 10h before each 
study period, participated in the investigation. 
At the start of each study period, the subjects each 
swallowed one capsule, with 100ml water. Anterior and 
posterior images, each of 60s duration, were taken at 
regular intervals over an 8h period, using a gamma camera 
(General Electric Maxicamera, Type II) as previously 
described (Section 2.2.2). The subjects stood directly 
in front of the camera during imaging, and were asked to 
keep body movements to a minimum during imaging. The 
images were recorded, stored and analysed as described in 
Section 2.2.2. The same methods of analysis and 
calculation were applied to the colon images. The 
subjects remained in an upright position, 
sitting/standing, throughout the study. About 4h after 
dosing the subjects received a standard light meal of one 
cheese roll and l50ml orange juice. The subjects did not 
complain of any untoward side-effects during the study 
days. 
3.3 Results and Discussion 
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The data for this investigation are expressed as the 
time for 50% of the activity to leave the stomach 
(5tSO%), and the time for 50% of the activity to enter 
the colon (Ct50%). The coiled form of the 51, and the 
overlying of different regions of activity preclude the 
accurate quantification of the pellets in the 51. Thus, 
the small intestine transit (SIT) of the pellets was 
calculated by subtracting StSO% values from Ct50% values. 
A value for the time from ingestion to 100% activity in 
the colon (MCt) is also given. The results are presented 
in Tables 3.1-3.5 and Figures 3.1-3.2. Dispersion of the 
pellets from the capsule enabled ready identification of 
the stomach. Dipersion of the pellets in the colon 
enabled definition of the colon region for the purposes 
of analysis. Representative scintiscans (Figure 3.3) 
show the pellets ~ i s p e r s e d d in the stomach, gastric 
emptying of the pellets into the 51, the pellets entering 
the colon, and the pellets dispersed in the colon. 
Generally, the subjects exhibited a lag phase, of 
different duration, before emptying began. The duration 
of the lag phase differed both between subjects and was 
different for each subject on subsequent study days. 
Emptying of the pellets occurred rapidly after this lag. 
The GE profiles for subject 3 (Figure 3.1), which are 
typical of those observed, illustrate the lag phase and 
subsequent rapid emptying. A plot of the mean GE values 
(Figure 3.2), shows the pellets empty rapidly in an 
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exponential fashion. Entry of the pellets into the colon 
was generally in the form of a bolus, as illustrated by 
the steep colon entry (CE) curves (Figure 3.1). The 
slopes of the mean CE curves (Figure 3.2.) also reflect 
this rapid entry. Both the rapid GE of the pellets and 
the bolus entry into the colon, suggest the pellets 
traverse the SI as a bolus. It is difficult to verify 
this on the scintiscans, due to the convoluted structure 
of the SI. In some cases, however, GE did not occur as a 
complete bolus, whereas CE was in bolus form. This 
suggests the pellets amass and form a bolus, before 
entering the colon. It is possible that this bolus forms 
in the region of the ICJ, and entry into the colon occurs 
with the next powerful contraction (Section 5). 
The mean St50% ( s.e.m.), 68 (23)min, 74 (19)min, 
and 67 (13)min, are similar to those previously reported. 
Bechgaard and Christensen (147) report GE t50% values of 
90-l80min, depending on the fasting or non-fasting state. 
A mean GE tSO% value of 45min for pellets given to fasted 
subjects, was reported by Hardy and Perkins (220). 
Gastric emptying tSO% values ranged from 30-150min, for 
pellets taken by either fasted subjects or subjects who 
had received a breakfast (301). It has been suggested 
that, particles less than about 2mm empty more as a 
liquid than a solid (16). The exponential pattern of 
emptying of the pellets illustrated in Figure 3.2, is 
similar to the GE pattern of liquids (216). Literature 
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values for the GE t50% of liquids range from lO-50min, 
depending on the fasting or fed state (289). 
Radiolabelled orange juice, given to fed subjects, had a 
mean GE t50% of 37min (371), and radiolabelled water had 
a mean GE t50% of l8min (295). 
As has been previously discussed (Section 2.3), the 
rapid and almost bolus emptying of the pellets observed 
in some subjects, is a consequence of the contractions of 
the MMC. The duration of the lag phase shows an inter-
and intra-subject difference, because the subjects are 
likely to be in different phases of the MMC when the 
capsule is ingested. The rapid emptying of capsule 
formulations in fasting subjects, has been previously 
demonstrated (237). It was suggested, that an adequate 
volume of liquid should be given with the dosage form, to 
improve dispersion of capsule contents in the stomach and 
maximise randomized emptying. However, bolus emptying of 
part of the formulation may still occur, even after a 
light breakfast (295). Gastric emptying is a variable 
process in healthy subjects, with marked inter- and 
intra-subject day-to-day differences (45). Multiple-unit 
systems are used as CR preparations to obtain a steady 
and predictable gastric emptying, thus reducing this 
variability. However, the results presented here, 
indicate that multiple-unit preparations given to fasted 
subjects, do not exhibit a steady and reproducible 
pattern of emptying. 
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The mean SIT ( ~ s . e . m . ) ) values of 175 (18)min, 148 
(21)min, and 182 (10)min, are similar to literature 
values. A mean SIT of 2.8h was reported for pellets 
given to fasted subjects (220). A study investigating 
the influence of density on the SI transit of pellets in 
fasted subjects, obtained mean SIT values of 2.9 (0.6)h 
for low density pellets, and 2.2 (0.5)h for high density 
pellets (372). In fed subjects, values of 4.7 (0.9)h and 
3.1 (0.2)h, were reported for the low and high density 
pellets respectively. Tiaprofenic acid pellets had a 
mean SIT of 176min after a light breakfast, and 250min 
after a heavy breakfast (246). Lactulose solution, 
labelled with technetium-99m, and administered to fasted 
subjects, had SIT values ranging from 47-139min (373). 
The SIT values in the present study are also in close 
agreement with the SIT time of 3-4h, commonly observed 
for oral dosage forms, irrespective of the fed or fasted 
state, reported by Davis et al (304). The consequences 
of this relatively short intestinal transit on the 
performance of CR formulations, has been discussed by 
Davis et a1 (304) and in Section 1.5 above. Furthermore, 
the bolus emptying of pellets and subsequent bolus SI 
transit, observed with fasted SUbjects, could affect drug 
release, and hence bioavailability, from multiple-unit 
preparations designed to disperse throughout the GIT. 
The mean CtSO% (:s.e.m.) values of 242 (15)min, 222 
(18)min and 249 (20)min for the three study days, are 
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similar to published results. Pellets administered to 
fasted subjects had a mean CE t50% of about 4h (220). 
Pellets administered after a light breakfast had a mean 
CE t50% of 253 (14)min (246). The colon entry of pellets 
administered to subjects who had fasted or who had eaten, 
ranged from 170-700min, depending on the caloric content 
of the meal (301). A range of CE t50% values of 
190-360min was obtained for radiolabelled water, 
administered to fed subjects (295). It is not entirely 
clear if entry of the pellets into the colon, in these 
cited studies, was in the form of a bolus. 
The mean (:s.e.m.) mouth to colon transit times of 
292 (26)min, 270 (8)min, and 325 (37)min, are of 
considerable consequence to the design of multiple-unit 
CR preparations. Many multiple-unit CR products are 
designed to relea$e drug over l2h. These results 
indicate, that in fasted subjects, all the sub-units 
would have entered the colon within 5-6h. Thus, only 
half the total dose of drug would be released in the SI, 
considered the major site of drug absorption (258), and 
the remainder released in the colon. If, as is commonly 
assumed, drugs are not extensively absorbed in the colon 
(262), this release in the colon represents a substantial 
loss of drug. Future studies would need to ascertain the 
extent of colonic absorption. In the meantime, the 
future design of CR formulations should endeavour to 
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control the GI transit of the dosage form, in both the 
fasted and fed state. 
Paired Student t tests were performed on the GI 
transit data, StSO%, CtSO%, SIT and MCt values: 
morning/afternoon, morning/evening, and 
afternoon/evening. There was no significant difference 
(p>O.l) between the values for each pair of data. This 
is also suggested by a simple comparison of the mean and 
s.e.m. values, and the mean transit profiles (Figure 
3.2). Thus, the time of day of administration does not 
appear to be a major determinant of GI transit. The 
variation in the theophylline levels cited above 
(368,369) is possibly related to the different 
contractile activity during the fasted and fed states. 
Formulations taken in the morning, possibly on an empty 
stomach, would be subjected to MMC activity and enter the 
colon within 6h. This would result in low drug levels in 
the evening. Formulations taken in the evening, possibly 
after dinner, would not be subjected to MMC activity 
until digestion was completed. A longer gastric 
residence, depending on the caloric content of the meal 
(301), would ensure a greater proportion of drug released 
into the SI, and higher drug levels. 
3.4 Conclusions 
The following conclusions can be drawn from the 
results of this investigation: 
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i. The gastrointestinal transit of pellets is not 
influenced by the time of day of 
administration of the formulation, in fasted 
subjects. 
ii. Gastric emptying occurs rapidly after a short 
lag phase, in fasted subjects. 
iii. Entry of the pellets into the colon often 
occurs in the form of a bolus. 
iv. Small intestine transit takes about 3h, and 
mouth to colon transit takes about 6h. These 
values are of consequence to the design of CR 
dosage forms. 
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Table 3.1 Mean ( s.e.m.) gastric emQtying data 
- %activity remaining in the stomach. 
Morning Afternoon Evening 
Time (min) 
0 100 100 100 
15 100 97 ( 2 ) 
20 79 (18) 
30 88 (5 ) 73 (20) 
35 57 (19) 
45 63 (18) 60 (23) 
55 53 (19) 
60 59 (18) 54 (23) 
70 42 (17) 
75 36 (17) 49 (24) 
90 25 (15) 22 (18) 35 (20) 
105 15 (14) 20 (18) 14 ( 8 ) 
120 14 (12) 15 (14) 12 ( 8 ) 
150 14 (12) 12 (11) 10 (8 ) 
180 0 0 8 ( 7 ) 
210 0 0 8 ( 7 ) 
240 0 0 0 
Table 3.2 
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Mean ( s.e.m.) colon entry data 
- %activity entered colon. 
Morning Afternoon 
Time (min) 
150 0 0 
180 11 (10) 28 (16) 
210 27 (17) 31 (17) 
240 30 (17) 33 (19) 
270 99 ( 1 ) 
285 97 ( 3 ) 
300 100 
315 99 
330 100 
345 100 
360 100 100 
425 100 100 
Evening 
0 
16 (14) 
20 (17) 
57 (22) 
66 (20) 
88 ( 10 ) 
89 (10) 
93 (6) 
100 
-110-
Table 3.3 Lag time and Gastric emQtying (St50%) 
data. 
Morning Afternoon Evening 
Lag St50% Lag St50% Lag St50% 
(min) (min) (min) (min) (min) (min) 
Subject 
1 0 10 15 65 70 85 
2 35 67 60 75 75 87 
3 20 27 15 40 90 100 
4 20 77 15 35 15 23 
5 70 157 105 155 15 40 
mean 29 68 42 74 54 67 
s.e.m. 10 23 16 19 14 13 
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Table 3.4 Small intestine transit (SIT) data. 
Morning Afternoon Evening 
SIT SIT SIT 
(min) (min) (min) 
Subject 
I 168 190 205 
2 198 105 210 
3 231 215 160 
4 170 132 152 
5 106 100 185 
mean 175 148 182 
s.e.m. 18 21 10 
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Table 3.5 Colon entry (Ct50%) and mouth to colon 
data. 
Morning Afternoon Evening 
Ct50% MCt Ct50% MCt Ct50% MCt 
(min) (min) (min) (min) (min) (min) 
Subject 
1 178 210 255 270 290 420 
2 265 390 180 300 297 425 
3 258 285 255 270 260 300 
4 247 290 167 240 175 240 
5 263 285 255 270 225 240 
mean 242 292 222 270 249 325 
s.e.m. 15 26 18 8 20 37 
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CHAPTER FOUR: 
HUCOADHESION 
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4.1 Introduction 
An investigation was conducted to determine the 
influence of the putative bioadhesive, po1ycarbophi1, 
on the GI transit of a placebo pellet formulation. The 
results of the investigation are presented and 
discussed in this chapter. 
The design of oral CR dosage forms continues to 
attract the attention of formulation scientists. Many 
technically ingenious systems have been developed (eg. 
osmotic devices) that are capable of well defined 
controlled drug release (Section 1.3). The performance 
of these systems in vivo, however, will be limited to 
the relatively variable GE times (301) and short SI 
transit (3-4h) (304) of dosage forms in man. A device 
designed to deliver its dose over 24h, may have emptied 
from the stomach, traversed the SI, and entered the 
colon in half that"time. This could result in a 
reduced systemic level and a significant fraction of 
the dose being wasted. Control of the GI transit of CR 
systems would be a clear advantage. 
The variable nature of GE of dosage forms, which 
is influenced by factors such as diet and the type of 
dosage form administered, has been well documented 
(374). Conversely, small intestine transit appears to 
be regular and unaffected by these factors (71,304). 
Control of the gastric emptying of dosage forms, 
therefore, represents the preferred option. A number 
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of strategies have been proposed for this purpose, such 
as particle size (323), and particle density (175). 
Another approach is the use of so called bioadhesive 
polymers, which adhere to the mucin/epithelial surface 
of the gastrointestinal tract (329). Controlled 
release devices formulated with such polymers, could 
provide a "localised platform", in the gastrointestinal 
tract, for drug release (375). The potential of 
bioadhesive systems is not restricted to oral drug 
delivery, but has already been exploited by the dental 
(376) and opthalmic professions (377). Systems have 
already been developed for nasal (378), vaginal (379), 
and buccal (380) drug administration. 
Bioadhesion involves the binding together, for an 
extended period of time, of two materials, one of which 
is biological in nature (381). Thus, any 
macromolecular material that adheres to, and is 
retained on biological tissue, can be termed a 
bioadhesive. For an extensive discussion of the 
interactions between polymers and tissues, the reader 
is directed to the review by Peppas and Buri (382). 
Very briefly, the postulated mechanisms of bioadhesion 
are: 
i. Mechanical bonding, whereby the bioadhesive 
occupies empty spaces in the tissue. This 
is only suitable for fluid bioadhesives that 
can flow into the crevices. 
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ii. Primary chemical bonds, generated by 
chemical reaction of functional groups of 
the tissue and bioadhesive. Due to their 
high strength, these bonds are not suitable 
for drug delivery systems. 
iii. Secondary chemical bonds, such as van der 
Waals interactions and hydrogen bonding. 
These are considered the most important 
forces contributing to bioadhesion. 
A number of pOlymeric devices have been 
investigated for their adhesiveness to mucus (383), and 
various methods have been applied to evaluate 
bioadhesion. These tests have largely concentrated on 
surface analysis and bioadhesive strength. The surface 
analysis tests have relied on conventional contact 
angle measurements and a variety of spectroscopic 
techniques (382). Bond strength tests can be 
classified into in vitro, in situ, and in vivo methods. 
Smart et al (384), using an in vitro tensiometric 
technique, have classified several polymers according 
to their bioadhesive strength with mucin. Park et al 
(385) have devised a method to measure polymer binding, 
using a fluorescent probe (pyrene) in cultured 
epithelial cells. The Robinson group has also 
developed a technique which measures the adhesion of 
polymer to rabbit stomach tissue (386). The force 
required to detach the polymer from the mucus is 
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measured. Recently, Mikos and Peppas (387) described 
an in vitro flow method, which should simulate the 
behaviour of CR devices in contact with mucus in vivo. 
Ching et al (386) measured the GI transit, in rats, of 
polymers labelled with 51Cr • The distribution of the 
polymers in the GIT was determined after sacrificing 
the rats and measuring the distribution of 
radioactivity. The technique of gamma scintigraphy has 
now been used to evaluate the bioadhesive performance 
of a polymer in man (388). 
Polymers which show bioadhesive properties can be 
categorised into three main groups: 
hydroxyl-containing, carboxyl-containing, and polymers 
with charged species (389). However, not all of these 
may satisfy the criteria, defined by Robinson et al 
(390), for use in CR devices: 
i. Polymers should show specificity in their 
site of adhesion, ego they should attach to 
ileal mucin surface and not to jejunal mucin 
surface. 
ii. Polymers should have no intrinsic activity, 
and should not cause irritation or an 
immunologic reaction. 
iii. Residence time of the polymer on the mucin 
surface should be controllable. 
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Few available polymers fulfil these criteria, but 
anionic, water-insoluble polymers are considered 
suitable, because of their low toxicity, and greater 
flexibility of use (329). In particular, 
polycarbophil, a hydrophilic, granular, acrylate 
polymer, used as both an antidiarrheal, and a 
bulk-forming laxative (391), has been shown to adhere 
to the rat stomach and small intestine (386). 
Furthermore, a sustained release formulation, 
containing polycarbophil and albumin beads, provided a 
longer duration of drug action, in rats, than 
formulations without the polymer (375). It was 
suggested that polycarbophil rapidly hydrated in vivo, 
retaining the beads and adhering to the mucin coating 
of the rat stomach. Toxicity data have revealed no 
deleterious results from the use of polycarbophil, 
whilst other studies indicate the polymer was neither 
absorbed from the rat GIT nor physiologically active 
(392). Clinical investigations have shown no GI 
irritation or systemic toxicity in patients who had 
taken polycarbophil for extended periods (392). 
The performance of bioadhesives in the human GIT 
has not been widely assessed. It was, therefore, 
considered useful to investigate the GI transit of a 
polycarbophil pellet formulation in man, using 
the technique of gamma scintigraphy. 
4.2 Materials and Methods 
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4.2.1 Preparation of Formulations 
The formulations were prepared in a manner to 
mirror the systems employed by Longer et al (375). 
Pellets, size range D.S-l.Dmm, density 1.17g/cm3 , of 
Amberlite IRA4l0 anionic resin (BDH) were labelled by 
soaking 6g in 10ml 99mTc-sodium pertechnetate solution 
(CIS(UK) Ltd, London). A mix of 100mg polycarbophil 
(O.S-l.Omm) (Lee Laboratories, Petersburg, USA) and 
dried labelled pellets (3l0mg), was filled into size 0 
hard gelatin capsules (Capsugel). The integrity of 
the binding of the label to the resin, was checked as 
described previously (Section 2.2.1). A disintegration 
t e s t ~ ~ in O.lN HCl, was also performed on the test 
formulation, but containing unlabelled pellets 
encapsulated with polycarbophil. The polycarbophil 
began to hydrate as soon as the capsule ruptured, and 
the pellets became.entrapped within the polymer gel. 
Each capsule had an activity of about 3MBq 
technetium-99m at the time of administration. The total 
radiation dose absorbed was estimated as 0.6D3mG/MBq 
for the stomach and small intestine, and 0.04SmG/MBq 
for the whole body (133,350). 
4.2.2 In vivo Study 
The study was approved by the Ethical Committee of 
the University of Nottingham, and conducted in 
accordance with the declaration of Helsinki Guidelines 
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for Ethics in Research. Approval to administer 
radiopharmaceuticals was obtained from the DHSS. 
Three, healthy male volunteers, age range 19-25, 
height range 1.7-2.0m, weight range 64-75kg, 
participated with informed consent. Each subject 
abstained from alcohol for 24h, and had fasted for 10h 
prior to each study day. The subjects did not smoke, 
and were not on medication. On the morning of each 
study day, each subject swallowed one capsule with 
100ml water. 
Anterior and posterior images, each of 60s 
duration, were taken at regular intervals, using a 
gamma camera (General Electric Maxicamera, Type II) 
having a 40cm field of view and fitted with a low 
energy (160 keV) parallel hole collimator. The 
subjects stood in front of the camera for imaging and 
were asked to keep body movements to a minimum during 
imaging. During the study, the subjects remained in an 
upright position, sitting/standing. The images were 
recorded, and stored on computer (Nodecrest). 
Anatomical reference markers containing technetium-99m, 
were taped to the skin, anteriorly and posteriorly, 
over the liver to the right of the stomach. The 
volunteers were given a standard light lunch of one 
cheese roll and 150m1 orange juice, after five hours of 
imaging. After this time they were allowed to eat and 
drink as normal. 
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The recorded images were analysed by drawing 
regions of interest around the position of the stomach 
and colon, as described previously (Section 2.2.2). 
The activity in these regions was quantified, and then 
corrected for background activity and radioactive 
decay. The error due to the variation in depth of 
radionuclide in the stomach and colon, was corrected by 
calculating the geometric mean of corresponding 
anterior and posterior views (216). 
A control study was conducted one week later, using 
capsules containing pellets only. The subjects did not 
complain of any untoward side-effects during each study 
day. 
4.3 Results and Discussion 
The data for this investigation are expressed as 
the time for 50% of the activity to leave the stomach 
(St50%), and the time for 50% of the activity to enter 
the colon (Ct50%). Due to the coiled structure of the 
S1 and the overlying of different regions of activity, 
which precludes the accurate quantification of the 
pellets in the SI, the SIT of the pellets was 
calculated by subtracting St50% values from Ct50% 
values. A value for the time from ingestion to 100% 
activity in the colon (MCt) is also given. Transit 
data are presented in Tables 4.1-4.5 and Figures 
4.1-4.3. Release of the pellets from the capsule 
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occurred within 15 minutes of administration and the 
dispersion of the pellets enabled ready identification 
of the stomach region for subsequent creation of 
regions of interest. Dispersion of the pellets in the 
colon enabled definition of the colon region for the 
purposes of analysis. Representative scintiscans 
(Figure 4.4) show the pellets dispersed in the stomach, 
gastric emptying of the pellets into the SI, the 
pellets entering the colon, and the pellets dispersed 
in the colon. 
A lag phase before GE is only markedly exhibited 
by subject 3, in both studies (Figure 4,1), As in the 
previous studies on posture and time, these fasted 
subjects show a rapid bolus-like emptying of the 
pellets. The control study GE curve for subject 1 
shows a two step emptying pattern, possibly indicating 
the pellets emptied as two boluses. The mean ( ~ s . e . m . ) )
StSO% time for the polycarbophil formulation, 52 
(13)min, and for the control formulation, 66 (l8)min, 
are in good agreement with previous studies that have 
used gamma scintigraphy to measure gastric emptying. A 
StSO% gastric emptying of 4Smin (n=4), was reported for 
pellets given to fasted subjects (220). The mean StSO% 
for pellets given to subjects who had taken a light 
breakfast, was 99 (7)min (245). Davis et al (301) 
obtained StSO% values ranging from 30-lS0min (n=6), for 
pellets taken by subjects who were either fasted or had 
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received breakfasts of different calorific values. 
This influence of food on the gastric emptying of 
pellets has been well illustrated by Davis et al (374). 
Gastric emptying was slower, 285 (45)min, when the 
subjects (n=6) received a heavy breakfast, than when 
given a light breakfast, 119 (15)min. Thus, rapid 
gastric emptying in the present study, can be 
attributed to the absence of food in the stomachs of 
the subjects. This has been adequately discussed in 
previous chapters (Sections 2.3 and 3.3). 
The data show that both formulations empty in an 
exponential fashion (Figure 4.3). It has been 
suggested, that particles small enough «=2mm) to pass 
through the "closed" pylorus, empty more as a liquid 
than as a solid (16). The rate of emptying of a liquid 
can be described 'as an exponential function, and 
typical St50% values range from lO-50min (289). 
Malagelada et al (305) report gastric emptying values 
between 20-60min for radiolabelled water given to fed 
subjects. Emptying followed approximately an 
exponential pattern. Similarly, the mean St50% for 
radiolabelled water, given to subjects who had received 
a light breakfast, was 18 (4)min (n=5) (245). The 
results of the present study suggest, therefore, that 
the pellets emptied from the fasted stomach in a 
pattern similar to that for the gastric emptying of 
liquids. 
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The similar rate of emptying for both 
formulations, indicates that their admixture with 
polycarbophil does not retard the gastric emptying of 
pellets in fasted subjects. Longer et al (375) 
investigated the gastrointestinal transit of a similar 
formulation of polycarbophil and albumin beads in rats. 
Approximately 90% of the beads remained in the stomach 
six hours after administration. In the absence of 
polycarbophil, the beads emptied rapidly. Russell and 
Bass (393) have reported that only 8% of a 
polycarbophil meal emptied from the stomachs of dogs 
within 90min. A further investigation of canine 
gastric emptying of polycarbophil (394) reported that 
50% of a 90g polycarbophil meal emptied within 4h. 
However, in this study no attempt was made to attribute 
the slow emptying to adhesion o ~ ~ the polycarbophil to 
the gastric mucosa. Autopsy of the dogs after the 
study, revealed particles of polycarbophil located in 
the stomach which were easily moved. This suggested 
that they did not adhere to the gastric mucosa. The 
amounts of polycarbophil used in these studies, in rat 
and dog, were greater than that used in the present 
study. These larger amounts may have elicited motor 
activity of the fed stomach, which would result in a 
slower rate of gastric emptying (394). About 98% of 
Amberlite resin particles, with an adsorbed film of 
poly(acrylic acid), a polymer with bioadhesive 
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propeties in vitro, were retained in the murine stomach 
lh after administration (395). The particles were 
labelled with technetium-99m, and administered as a 
suspension. The small particle size of the resin 
(O.009mm), as well as the nature of the formulation, 
precludes comparison with the present study. Recently, 
Fell et al (396) investigated the effect of 
polycarbophil and Carbopol-934P on the gastrointestinal 
transit of Arnberlite pellets (0.7-l.0mm). The 
formulations were investigated using a similar method 
to the present study. Polycarbophil did not alter the 
gastric emptying of the beads (t50% 33min), whereas 
Carbopol delayed gastric emptying (t50% l66min). The 
small intestine transit was similar for the polymer and 
control formulations. 
The mean SIT (!s.e.m.) values of 160 (14)min for 
the polycarbophil formulation and 160 (lO)min for the 
control formulation, are in close agreement to the mean 
value of 3h for oral formulations observed by Davis et 
al (304). Furthermore, these values are similar to the 
SIT values observed in the time study, 175 (18)min, 148 
(2l)min and 182 (lO)min. Comparison with other 
literature values can be found in Section 3.3. The 
similarity between these SIT values and literature 
values, suggests polycarbophil does not inhibit SI 
transit. A similar result was expressed by Fell et al 
(396). This is in contrast to the results of Ching et 
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al (386), which indicate the bioadhesion of 
polycarbophil in the rat SI. They, however, suggest 
the extent of bioadhesion in the SI will be governed by 
the number of free binding sites on the surface of the 
polymer. These are likely to be few, due to the mucin 
covering the polymer when it is discharged from the 
stomach. Another study, investigating the effect of 
guar on the absorption of glucose in rats, suggested an 
interaction between hydrated guar and 
mucopolysaccharides of the mucosal surface, which 
"anchors" the surface layer of gel (397). Preferential 
adhesion in the SI of rats, was achieved by 
incorporating amino sugars into copolymers of 
hydroxypropylmethacrylamide (398). Galactosamine 
residues caused bioadhesion in the duodenum, whereas 
fucosylamine improved adhesion in the distal jejunum. 
The CE curves (Figures 4.2 and 4.3) also reflect the 
bolus entry that was seen in the time study. The mean 
Ct50% (=s.e.m.) values of 212 (22)min for the 
polycarbophil study and 226 (17)min for the control 
study, are similar to the time study values (242 
(15)min, 222 (18)min and 249 (20)min for the three 
study days), and to published results (Section 3.3). 
Similarly, the mean (!s.e.m.) MCt values, 265 (29)min 
for the polycarbophil study and 295 (4l)min for the 
control study, are in close agreement with the time of 
day data (292 (26)min, 270 (8)min, and 325 (37)min). 
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These results further reflect the relatively short GI 
transit times of formulations. The error in designing 
CR systems which release drug over a 12h period, 
without attempting to control the transit of these 
systems is further emphasised by these results (see 
also Section 3.3). 
Despite the small sample size, a Students t test 
was performed on the transit data. In each case no 
significant difference was observed (p>O.I) between the 
polycarbophil data and the control data. Thus, 
admixture of pellets with polycarbophil does not reduce 
GIT transit times. There is possibly one major flaw 
with the design of the present investigation, namely 
the position of the polycarbophil in the GIT is not 
known. Although the investigation was designed to 
determine the influence of polyqarbophil on the GI 
transit of pellets, it would have been fruitful to have 
labelled the polycarbophil with another isotope (eg. 
indium-Ill). This would indicate if the polymer did 
remain in the stomach, without entrapping the pellets. 
The importance of controlling the GI transit of CR 
systems has been discussed above. In many instances 
this would improve bioavailability of the drug. The 
absorption of digoxin, which occurs largely in the 
proximal SI, was improved by decreasing GI motility 
using propantheline (399). However, decreasing GI 
motility can also decrease absorption by decreasing the 
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agitation required for solid dissolution (280). The 
glucose absorption study cited above, noted a decrease 
in aborption in the presence of guar (397). An 
increase in resistance of the mucosal diffusion 
barrier, resulting from an increase in viscosity at the 
mucosal surface, was provided as an explanation. Thus, 
the strategy used to control GI transit should not in 
itself interfere with the processes of dissolution and 
absorption. 
An important caveat, exemplified by the withdrawal 
of the OSMOSIN system (400), should be considered in 
our quest to identify suitable bioadhesives for COOS. 
Although the OSMOSIN system was not a bioadhesive 
system, the adverse reactions associated with the 
formulation could be repeated by bioadhesive drug 
delivery products. Several workers have also reported 
on the oesophageal sticking of capsule and tablet 
formulations as a possible cause to oesophageal 
ulceration (343,401). Thus, all that sticks is not 
necessarily safe. Our search for a suitable 
bioadhesive should not be impaired by these findings, 
but it may be rewarding to direct our research to 
understanding the mechanism of bioadhesion exhibited by 
several bacteria (eg. Escherichia coli) (381). 
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4.4 Conclusions 
The following conclusions can be drawn from the 
results of this investigation: 
i. The gastrointestinal transit of pellets is 
not influenced by the admixture of 
polycarbophil. 
ii. The pellets emptied rapidly from the 
stomach, usually as a bolus, and entered the 
colon in a similar fashion. 
iii. Small intestine transit of the pellets, 
about 3h, was similar to previously quoted 
values. 
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Table 4.1 Gastric emQtying and colon entry data 
for the QOlycarboQhil formulation 
%activity remaining in the region. 
Subject 1 2 3 mean s.e.m. 
Time (min) 
0 100 100 100 100 
15 94 96 100 97 1 
30 88 15 98 67 21 
45 85 2 98 62 25 
60 8 0 74 28 19 
75 6 0 62 23 16 
90 6 a 28 11 7 
105 0 a 10 3 3 
120 0 a 6 2 2 
135 0 a a a 
150 0 15 a 5 4 
165 0 84 a 28 23 
180 0 93 18 37 23 
195 0 100 20 40 25 
210 0 100 22 41 25 
255 65 100 78 81 8 
285 83 100 100 94 5 
315 100 100 100 100 
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Table 4.2 Gastric em2tying and colon entry data 
for the control formulation - %activity 
remaining in the region. 
Subject 1 2 3 mean s.e.m. 
Time (min) 
0 100 100 100 100 
15 100 94 100 97 2 
30 95 90 100 95 2 
45 95 58 94 82 10 
60 94 10 77 59 20 
75 69 6 36 37 15 
90 41 4 27 24 9 
105 38 2 7 15 9 
120 38 0 0 13 11 
135 35 0 a 12 10 
150 35 a a 12 10 
165 a a a a 
180 a 17 a 6 5 
195 0 84 0 28 23 
210 0 84 28 37 19 
245 41 100 100 80 16 
260 46 100 100 82 15 
275 56 100 100 85 12 
305 ,60 100 100 87 11 
335 72 100- 100 91 7 
365 92 100 100 97 2 
395 100 100 100 100 
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Table 4.3 Lag time and Gastric e m Q t ~ i n g g (St50%) 
values for the E o l ~ c a r b o E h i l l and control 
studies. 
polycarbophil study Control study 
Lag Time St50% Lag Time St50% 
(min) (min) (min) (min) 
Subject 
1 <5 53 15 80 
2 <5 23 <5 47 
3 15 80 15 70 
mean 52 66 
s.e.m. 13 8 
Table 4.4 
Subject 
1 
2 
3 
mean 
s.e.m. 
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Small intestine transit (SIT) data for 
the polycarbophil and control studies 
Po1ycarbophi1 study 
SIT 
(min) 
192 
134 
153 
160 
14 
Control study 
SIT 
(min) 
185 
145 
150 
160 
10 
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Table 4.5 Colon entry (Ct50%) and mouth to colon 
data for the 2olycarbo2hil and control 
studies. 
Polycarbophil study Control study 
Ct50% MCt Ct50% Met 
(min) (min) (min) (min) 
Subject 
1 245 315 265 395 
2 157 195 192 245 
3 233 285 220 245 
mean 212 265 226 295 
s.e.m. 22 29 17 41 
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CHAPTER FIVE: 
GASTROINTESTINAL TRANSIT 
OF TABLETS I 
-143-
5.1 Introduction 
In the next two chapters, I shall discuss the 
results of a series of studies designed to investigate 
the gastrointestinal transit of tablets. The 
investigation addressed three themes: 
i. the effect of tablet size on GI transit, with 
particular reference to gastric emptying and 
transit across the ileocaecal s p h i n c t e r ~ ~
ii. the effect of food on GI t r a n s i t ~ ~
iii. the transit of tablets in the colon 
(Chapter 6). 
The need to control the GI transit of oral dosage 
forms has been comprehensively discussed in Sections 1.5 
and 3.3. It was ~ l s o o suggested, that controlling gastric 
emptying was the preferred option (Section 4.1). A 
number of plausible strategies has been proposed for this 
purpose, such as particle density (175), floating tablets 
(324), bioadhesives (329), and incorporating fatty acids 
into formulations (330). However, only a limited success 
has been achieved using these strategies. One further 
proposal, is the use of particle size (323). Several 
studies have suggested that the size of particles is a 
major determinant of the gastric emptying of solids in 
the fed state, whereas size does not appear to affect 
transit through the small intestine (304). It is 
important to recognise the differences in gastric 
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emptying patterns of the fed and fasted stomach, and the 
• 
role of the MMC in emptying large indigestible solids 
(Section 1.2.1). 
Radiolabelled liver, either homogenised or lcm 
cubes, together with 7mm plastic spheres, have been 
administered to dogs (402). Gastric emptying of the 
respective particles was determined by sampling the 
duodenal contents. The liver always emptied from the 
stomach, homogenised liver emptying faster, whereas the 
spheres were retained. The authors concluded that solids 
must be reduced to a critical size before they can empty. 
A similar study illustrated the sieving function of the 
stomach. Only liver particles of about lmm, emptied from 
the intact canine stomach, whereas after gastric surgery, 
larger particles were able to empty (13). A later study 
indicated the human stomach also allows only small 
particles «lmm) to empty into the duodenum (403). A 
study using gamma scintigraphy found that subjects 
emptied 0.2Smm liver particles more quickly than lOmm 
cubes (404). Cortot (40S) suggests 0.5mm is the critical 
diameter for digestible solids, but admits dietary fibres 
measuring 1-2mm can empty from the fed stomach. 
Radio-opaque markers (lOmm x 2mm) emptied significantly 
slower than digestible solids, with most markers emptying 
during the fourth post prandial hour (406). The nOW 
commonly accepted size for the diameter of digestible 
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solids that can empty from the fed stomach is about 2mm 
(16). 
Studies have also been conducted, in man, with 
dosage forms. Disintegrating tablets formed a mass of 
2-3cm, which was retained in the stomach until the mass 
dispersed into smaller particles (408). Pellets (4mm) 
taken with food had a linear pattern of emptying, similar 
to digestible solids, but the rate of emptying was slower 
than that of the food (338). Another study, however, 
found pellets of a similar size had a slower rate of 
emptying, than co-administered food (409). Bechgaard and 
Ladefoged found no significant change in transit times of 
pellets, increased in size from 0.5mm to l.5mm (175). 
Mini-matrices (3mm diameter) emptied gradually from the 
stomach of fed subjects, but as a bolus in fasted 
subjects (410). park et al (249) found no effect of 
either size or shape on the rate of gastric emptying of 
enteric coated tablets (4.7-12.7mm). These studies were, 
however, conducted in fasted sUbjects. Riboflavine 
tablets (lOmm and l2mm) were retained in the stomach for 
a prolonged period, which resulted in an improved 
bioavailability of the vitamin (411). Size of the 
tablets was considered the major factor controlling the 
gastric retention. 
Studies recently conducted in dogs, have attempted 
to specifically address the question of particle size, 
for indigestible solids, and gastric emptying. Meyer et 
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al (323), reported that the rate of emptying, in dogs, 
became progressively faster as sphere diameter was 
reduced from Smm to Imm. Spheres of O.OISmm, however, 
had a rate of emptying similar to Imm spheres. A 
relationship between particle size and gastric emptying 
was also observed by Itoh et al (407). Gastric residence 
time progressively increased as particle size increased. 
This approached an apparent plateau at about Smm, after 
which gastric residence was not significantly affected by 
increases in particle size. 
Two conclusions can be deduced from the above 
examples. Firstly, the fed stomach discriminates between 
the gastric emptying of solids depending upon particle 
size. Secondly, the precise size of particles that can 
empty from the fed stomach is not absolutely determined. 
It is feasible thpt there is no definite cut-off size, 
but a gradation of sizes over which emptying becomes both 
slower and more variable as particle size increases. An 
investigation using tablets of a relatively narrow size 
range would indicate if such a cut-off point exists, and 
the feasibility of using particle size to control the 
gastric emptying of oral dosage forms. Therefore, this 
was a designated objective of the present thesis. 
The role of the ICS in regulating the entry of 
material into the colon is largely unknown. Quigley and 
colleagues (9S) have conducted several studies, which 
indicate the ICJ controls the passage of chyme into the 
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colon (see Section 1.2.3). Feely et al (410) suggest 
that sub-units of a multiple unit system, which have 
spread in the SI, due to their variable gastric emptying, 
regroup at the ICS before entering the colon. 
Information relating particle size and transit across the 
ICS, would prove useful to the design of dosage forms for 
directed delivery to the colon. 
The transit of dosage forms in the colon has not 
been extensively studied. A study by Hardy et al (315) 
has shown a relationship between particle size and the 
rate of transit in the colon. Further data would help 
verify this initial finding. 
In the light of these past investigations, it was 
decided to conduct a series of studies to measure the GI 
transit of tablets in human volunteers, with particular 
emphasis on the ~ b o v e e mentioned themes. 
5.2 Materials and Methods 
The investigation was conducted as two separate but 
related parts. The first study investigated the GI 
transit of ten 3mm, 4mm and 5mm tablets, taken after 
either a light or heavy breakfast. The second study 
examined the transit of ten 5mm, 6mm and 7mm tablets 
taken after a medium sized breakfast, and was conducted 
as a crossover design. A crossover was not possible in 
the first study because of the restrictions in giving 
radiolabe11ed formulations to human volunteers. 
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5.2.1 Preparation of Formulations 
Non-disintegrating tablets were prepared from 
ethylce1lulose (BDH) and Amberlite IRA410 resin (BDH). 
The resin was prepared as previously described (Section 
2.2.1), and then milled using a conventional ball mill 
(PascalI Engineering Company). The milled resin was 
labelled with technetium-99m using the method described 
in Section 2.2.1. Labelled resin was passed through a 
O.09mm screen, and blended with ethylcellulose powder to 
the following formula: 
Amberlite resin 
Ethylcellulose 
2% w/w 
98% w/w. 
The powder mix was then directly compressed into tablets 
using a Manesty F3 single-punch tablet machine. The 
tablets had a hardness of 8kgF as measured on a CT40 
hardness tester (Engineering Systems). Details of the 
tablets are described in Table 5.1. 
All batches of tablets were coated to prevent the 
leaching out of the radiolabel, and to stop the tablets 
from disintegrating. Two coating solutions were used: 
Ethylcellulose 
Acetylbutylcitrate 
(A/S Alfred Benzon) 
Propan-2-o1 (BDH) 
4.5% w/w 
0.5% w/w 
95% w/w. 
The solution was painted onto each tablet with a small 
brush and allowed to dry under a stream of warm air. The 
second coating solution was then applied to the dried 
tablets in the same way: 
Table 5.1 
Diameter 
(mm) 
3.1 
4.0 
5.0 
6.2 
7.1 
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Formulation details 
Shape of Punch 
Normal curvature 
Flat faced 
Flat faced 
Flat faced 
Concave 
Mean Uncoated 
Tablet Weight 
(mg) 
20 
35 
55 
75 
81 
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*Cellulose acetate 
Solvent 
* Dichloromethane (BDH) 
Methanol (BDH) 
15% w/w 
85% w/w 
80% v/v 
20% v/v. 
A simple in vitro dissolution test was performed on 
each batch of labelled and coated tablets. Five tablets, 
were added to a beaker containing 50ml O.IN HCI at room 
temperature. The contents were stirred using a magnetic 
stirrer and "flea". The tablets were removed at regular 
intervals, and activity measured as described in Section 
2.2.1. In each case not more than 1.5% of radiolabel was 
lost after six hours. Thus, the tablet coating prevented 
any substantial leaching out of the isotopes. 
5.2.2 In vivo Studies 
The studies were approved by the Ethical Committee 
of the University of Nottingham, and conducted in 
accordance with the declaration of Helsinki Guidelines 
for Ethics in Research. Approval to administer 
radiopharmaceuticals was obtained from the DHSS. 
5.2.2.1 Study 1 
Six, healthy male volunteers, age range 19-25, 
height range 1.69-1.87m, weight range 65-76kg, 
participated with informed consent. Each subject 
abstained from alcohol for·24h, and had fasted for lOh 
prior to each study day. The subjects did not smoke, and 
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were not on any medication. On the morning of each study 
day, three subjects consumed a light breakfast (1500kJ): 
1 bowl cereal with milk 
1 slice toast, butter, marmalade 
1 glass orange juice. 
The other three subjects took a heavy breakfast (3500kJ): 
1 egg 
1 rasher bacon 
1 sausage 
tomatoes 
1 slice toast, butter, marmalade 
1 glass orange juice. 
Immediately after breakfast, the subjects took 
either ten 3mm, 4mm or 5mm tablets together with 200ml 
water. Each dose of ten tablets had an activity of about 
3MBq. The total radiation dose absorbed was estimated as 
0.603mG/MBq for the stomach and small intestine, and 
0.045mG/MBq for the whole body (133,350). Anterior and 
posterior images, each of 60s duration, were taken at 
regular intervals, using a gamma camera (General Electric 
Maxicamera, Type II) having a 40cm field of view and 
fitted with a low energy (160 keV) parallel hole 
collimator. The subjects stood in front of the camera 
for imaging and were asked to keep body movements to a 
minimum during imaging. During the study, the subjects 
remained in an upright position, sitting/standing. The 
images were recorded, and stored on computer (Nodecrest). 
Anatomical reference markers containing technetium-99m, 
were taped to the skin, anteriorly and posteriorly, over 
the liver to the right of the stomach. At about 2.5h 
after dosing the subjects were given a drink of orange 
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juice. A standard light lunch consisting of one cheese 
roll, one ham roll and 150ml orange juice, was taken 
after about 4h. An evening meal of steak, chips, peas, 
and cheesecake was taken about 9.5h after dosing. 
The recorded images were analysed by drawing regions 
of interest around the position of the stomach and colon, 
as described previously (Section 2.2.2). The activity in 
these regions was quantified, and then corrected for 
background activity and radioactive decay. The error due 
to the variation in depth of radionuclide in the stomach 
and colon, was corrected by calculating the geometric 
mean of corresponding anterior and posterior views (216). 
The study was repeated using the same protocol on 
two further occasions, ,such that each subject received 
each size of tablets, after eating the same breakfast 
they consumed on the first day. The subjects did not 
complain of any untoward side-effects during each study 
day. 
5.2.2.2 Study 2 
A further six, healthy male volunteers, age range 
19-25, height range 1.72-1.90m, weight range 59-83kg, 
participated with informed consent. Each subject 
abstained from alcohol for 24h, and had fasted for 10h 
prior to each study day. The subjects did not smoke, and 
were not on medication. The study used the same protocol 
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as Study 1, except a medium sized breakfast (2300kJ) was 
consumed by all six subjects: 
1 bowl cereal 
2 slices toast, butter, marmalade 
1 glass orange juice. 
Immediately after breakfast, the subjects took 
either ten 5mm, 6mm or 7mm tablets together with 200ml 
water. Each dose of ten tablets had an activity of about 
3MBq. The total radiation dose absorbed was estimated as 
0.603mG/MBq for the stomach and small intestine, and 
0.045mG/MBq for the whole body (133,350). The study was 
repeated using the same protocol on two further 
occasions, such that each subject received each size of 
tablets. The subjects did not complain of any untoward 
side-effects during each study day. 
5.3 Results and Discussion 
The data for the investigation have been expressed 
in a number of ways, and representative examples are 
given. The St50%, SIT, Ct50% and MCt values are 
presented in Tables 5.2-5.10. Gastric emptying profiles 
and colon entry curves are shown in Figures 5.1-5.4 and 
5.8-5.9. Representative scintiscans, which illustrate 
the various phases of transit, are presented in Figure 
5.5. The spreading of tablets from the stomach, followed 
by subsequent regrouping at the ICS was a typical 
phenomena. In a number of cases, the individual tablets 
could all be distinguished spread in different regions of 
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the colon. Histogram plots, which also demonstrate the 
spreading of the tablets from the stomach and regrouping 
at the leS, are given in Figures 5.6, 5.7 and 5.10. 
5.3.1 Study 1 
The tablets emptied quite rapidly from the stomach, 
in the light breakfast group, with no appreciable lag 
phase (Figure 5.3). The linear pattern of emptying 
exhibited by all three tablet sizes, is typical for 
digestible soilds (216), and indicates the tablets become 
dispersed in, and empty with the food (292). A lag phase 
is more evident with the heavy breakfast, although the 
4mm tablets show a rapid initial emptying (Figure 5.4), 
and emptying appears to have a biphasic pattern. 
Emptying is linear after the initial lag, followed by a 
second lag phase and subsequent linear emptying. The 
total duration of emptying is markedly longer following 
the heavy breakfast, for all tablet sizes. Both the GE 
profiles and the St50% data show gastric emptying is not 
significantly influenced by tablet size (p>O.l), for each 
type of breakfast. However, the difference in emptying 
patterns between the light and heavy breakfast, suggests 
the nature of the meal is a determinant of emptying. A 
Student t test conducted on the St50% data for each 
breakfast group, irrespective of tablet size, shows a 
significant difference (p<0.005) between the groups. 
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The St50% values for the tablets are similar to 
literature values for pellet studies (0.5-1.0mm) 
conducted in humans: 77min after a light breakfast and 
l70min after a heavy breakfast (246). Mini-matrices 
(3mm) had a mean St50% of 130min after a medium sized 
breakfast (410). However, these results are in contrast 
to similar studies conducted in animals. Meyer et al 
(323) report St50% values of 3-4h for 3.2mm spheres given 
to fed dogs, whilst about 80% of 5mm spheres remained in 
the stomach 6h after ingestion. Liver particles of these 
same sizes had StSO% values of about 2h. Mean values of 
4h and 7h are reported for the emptying of 3mm and Smm 
indigestible particles respectively, in fed dogs (407). 
Prolonged periods of gastric residence (>7h) were also 
seen for 4.1mm tablets given to gastric emptying 
controlled rabbits (185). A difference in both GI 
physiology, and the nature of the administered meals may 
explain the differences between the animal and human 
data. 
Small intestine transit was not affected by either 
meal size or tablet size, which is in keeping with 
previous observations (301). Furthermore, SIT values are 
in good agreement with the commonly observed 3( l)h SI 
transit of oral pharmaceutical dosage forms (304). 
Colon entry data are similar to pellet data, mean 
Ct50% values of 2S3min after a light breakfast and 420min 
after a heavy breakfast (246). A significant difference 
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(p<O.OOI) is also apparent between the light and heavy 
breakfast groups, irrespective of tablet size. This 
simply reflects the difference in gastric emptying 
between the two groups, and is emphasised by colon entry 
not reaching 100% for all three tablet sizes in the heavy 
breakfast group. 
5.3.2 Study 2 
The pattern of GE is similar for all three tablet 
sizes (p>O.l), although the 7mm tablets appear to have a 
faster rate of emptying (Figure 5.9). The GE curves are 
similar in shape to those of the previous study, which 
suggests that indigestible solids, up to 7mm diameter, 
can empty from the fed stomach. The mean St50% values, 
as well as the mean SIT and Ct50% values, are in good 
agreement with the literature values quoted above. Once 
again, the present values do not compare with animal 
data. The gastric emptying of 7.7mm particles was >7h in 
rabbits (ISS), and >Sh for Smm spheres in dogs (407). 
However, in certain cases, in the present study, some 
tablets did remain in the stomach 10h after ingestion 
(eg. subject 5, 7mm tablets). 
The pattern of transit, illustrated by Figure 5.10, 
was similar to Study I (Figures 5.6-5.7). Tablets spread 
in the small intestine, as a consequence of their gastric 
emptying, but regrouped at the ICS, before entering the 
colon. 
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5.3.3 General Discussion 
5.3.3.1 The effect of tablet size 
The GE data for both Study 1 and Study 2 suggest that 
indigestible solids, up to 7mm in diameter, can empty 
from the fed stomach. This is in contrast to current 
literature, which suggests a critical size of about 2mm 
(16). However, this figure was obtained from work 
largely conducted in dogs. There are two possible 
explanations for the results of the present investigation 
and their contradiction with the animal work. 
The first explanation is simply that the critical 
size in man is greater than 2mm, and the present results 
indicate that the critical size is larger than 7mm. This 
is possible considering that the mean resting pyloric 
diameter in man is 12.8t7mm (411). A difference in GI 
physiology may account for the discrepancy between human 
and canine data. However, gastric emptying does not 
depend on pyloric diameter, but on the pressure gradient 
between the antrum and duodenum (see Section 1.2.1). 
The second explanation considers the contractions of 
the stomach, and is based on the observations of Dozois 
et al (16). They noticed that plastic spheres, subject 
to the contractions of the fasted canine stomach, are 
normally swept into, and then retropelled from the 
terminal antrum back into the main body of the antrum. 
These contractions are likely to be the intermittent 
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phase 2 contractions of the MMe. Occasionally, spheres 
became "trapped" in the terminal antrum, and as the next 
contraction swept towards the terminal antrum, the 
trapped sphere passed through the partially occluded 
pylorus into the duodenum. This would be facilitated by 
the pressure gradient between the antrum and duodenum 
generated by the approaching contraction. This 
"trapping" is obviously a random process, but with a 
large number of particles, there is a greater statistical 
chance for fortuitous emptying. Blythe et al (413) made 
a similar observation with radio-opaque enteric c o a t ~ d d
tablets. Normally the tablets were retropelled back from 
the pyloric region, but on some occasions, tablets were 
seen remaining near the pyloric sphincter. 
Although the present investigation was conducted in 
fed subjects, the above scenario is still applicable, 
since phase 2 contractions are similar to fed state 
contractions (335,414). Thus, ten tablets given to one 
subject, will essentially empty in a random fashion from 
the stomach, but over a given period the emptying appears 
to be regular. It can be envisaged that both the 
diameter of the human pylorus and fortuitous emptying are 
responsible for the present results. The mean GE data 
for Study 2 suggest that the 7mm tablets empty more 
rapidly than the 5rnm and 6mm, although the differences 
are not significant. Interestingly, the variability 
(expressed as s.e.m.) in the data increases as the size 
-159-
is increased (eg. compare the s.e.m. for the St50% 
values, 16 for the 5mm, 23 for the 6mm and 35 for the 
7mm). This would be expected since the pattern of 
emptying should become more unpredictable as the size 
approaches a critical value. It is possible that larger 
tablets are initially more prone to being trapped, which 
increases their chance of fortuitous emptying. As the 
number of tablets in the stomach begins to decrease, the 
incidence of trapping also decreases, and the tablets are 
retained largely due to their diameter. Smaller tablets 
will behave like digestible solids and exhibit a similar 
pattern of emptying. These results suggest that there is 
a gradation of sizes which will empty from the fed 
stomach, rather than a precise cut-off value. Gastric 
emptying becomes less predictable as tablet diameter 
increases, and this may reach a plateau at larger sizes. 
Smith and Feldman (415) noticed no signficant difference 
between the gastric emptying of 2mm and lOmm radio-opaque 
markers in fed human subjects. This suggests the 
critical size of indigestible solids that can empty from 
the fed human stomach is markedly greater than 2mm. More 
importantly, their results and the results of the present 
study, suggest the gastric emptying of indigestible 
solids does not rely entirely on the phase 3 contractions 
of the MMe. In contrast, Jonsson et al (416) concluded 
that size was of importance in the gastric emptying of 
tablets when taken with food. Two tablets each, of 3mm 
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and l4mm diameter were administered to eight subjects. 
The 14mm diameter tablets were retained in the stomach 
for a significantly longer time (median time >780min) 
than the 3mm tablets (median time 4BOmin). It is 
probable that 14mm is larger than the critical diameter, 
hence the longer duration of gastric residence. 
The original rationale for conducting these studies 
was to determine the size of tablet that would not empty 
from the fed stomach, and to use this information in the 
design of CR dosage forms. However, these results bring 
fresh doubts as to the suitability of using the size' of 
dosage forms as a control on gastric emptying. 
Furthermore, the obvious practical problems in 
administering a multiple unit system, consisting of 
tablets greater than 7mm, would have to be realised. 
Thus, this method of controlling the gastric residence of 
oral dosage forms becomes less of a pharmaceutical 
reality. A further study using tablets larger than 7mm 
would be of value more for its physiological interest 
than for its pharmaceutical relevance. 
5.3.3.2 The effect of food 
The important effect of food on gastric emptying is 
well illustrated by the St50% data for both studies. The 
greater the energy content of the meal, the longer the 
duration of emptying. The mean gastric emptying curves 
for the tablets are presented in Figures 5.3, 5.4, 5.9. 
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A careful examination of the curves indicates the nature 
of the breakfast has a greater influence on emptying than 
the size of tablet. The tablets (3mm, 4mm, 5mm) taken 
after the light breakfast empty rapidly, those taken 
after the heavy breakfast (3mm 4mm, 5mm) empty slowly, 
and those taken after the medium breakfast (5mm, 6mm,7mm) 
have an emptying rate between the two. The duration of 
gastric emptying can be arranged in a similar order. 
Smith and Feldman (415) also concluded that food had a 
, 
greater influence on the gastric emptying of indigestible 
solids than did particle size. The effect of food on the 
gastric residence of dosage forms has been well 
illustrated. The mean gastric emptying of a controlled 
release naproxen tablet (17mmx4mm) was markedly increased 
if administered after a breakfast (417). Food had a 
similar effect on llmm floating and non-floating tablets 
(418). Food was also the major determinant of the 
gastric emptying of both light and heavy pellets 
(O.7-l.0mm), rather than the density of the pellets 
(328). The mean gastric residence time of an Heidelberg 
capsule was increased by administering the capsule after 
a meal, and then prolonged by frequent feeding (183). 
The colon entry curves mirror the GE curves, ie. the 
light breakfast tablets enter the colon before the medium 
breakfast tablets, which in turn enter the colon before 
the heavy breakfast tablets. Thus, entry into the colon 
is determined by the time for gastric emptying, and not 
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by the time for SI transit. This result reinforces the 
observation of the consistent nature of SI transit, which 
is affected neither by the energy content of food (71) 
nor the dosage form (304). 
5.3.3.3 Transit across the ileocaecal sphincter 
As mentioned above, the tablets generally regrouped 
at the ICS, before entering the colon, illustrated by 
Figures 5.6, 5.7 and 5.10. This stagnation is probably 
related to the proposed reservoir function of the ICS 
(99), and has been previously observed for both mUltiple 
unit (410) and single unit (419) CR systems. However, no 
obvious pattern could be found between tablet size and 
transit across the ICS,. Tablets were sometimes seen 
grouped in the ICS region immediately prior to lunch, but 
had not always entered the colon after lunch. Thus, the 
gastroileal reflex noted by some workers (95), is not a 
generic event. Spiller et al (100) also concluded that 
the gastroileal reflex is of minor importance to 
ileocaecal transit. In some cases, entry into the colon 
was in the form of a bolus (Figure 5.1), but no obvious 
pattern emerged relating tablet size to bolus entry. 
Kruis et al (101) suggest that 30-50% of ileocolonic 
transit is as a bolus, but·the remainder occurs as a 
steady trickle. Bowel movement was considered a likely 
factor of importance, and this was selected for 
evaluation in Study 2. The times at which the subjects 
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defaecated, over the duration of the study, was recorded. 
However, there was no observable connection between entry 
into the colon and bowel movements. 
The shape of colon entry curves and CtSO% values are 
considered useful parameters for measuring ICS transit 
(99). A comparison of the Ct50% values for the tablets, 
for each type of breakfast, shows no significant 
difference between the values (p>O.l). Further 
comparison of the data suggests an apparent difference 
due to the breakfast consumed. This difference in Ct50% 
values probably reflects the difference in St50% values 
due to the the breakfast consumed, rather than an affect 
on ileocaecal transit. However, a detailed examination 
of the colon entry curves (Figures 5.3, 5.4 and 5.9) 
shows the light breakfast yields steeper entry curves 
than the medium and heavy breakfasts. A similar 
examination of the curves for individual subjects 
(Figures 5.1, 5.2, and 5.8) also shows a rapid entry 
after the light breakfast. These steep curves reflect 
bolus entry of material into the colon, after remaining 
immobile in the terminal ileum (99). The longer plateau, 
seen with the medium and heavy breakfast curves, is 
indicative of episodic colonic inflow. This difference 
in the rates of entry, may relate to the solid content of 
the meal, since high residue meals have a slower rate of 
colonic filling than low residue meals (99). The light 
breakfast has a relatively larger volume of fluid than 
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the other two meals, and could be considered a lower 
residue meal. Another explanation, is that the 
contractions of the MMC would begin relatively early 
after the light breakfast, propelling the tablets into 
the colon. However, the literature suggests that MMC 
contractions, unlike in dogs, do not have a major role in 
ileocaecal transit (89). Further studies are required, 
perhaps taking greater consideration of bowel habits and 
diet, before a complete 
understanding of ileocaecal transit can emerge. 
5.4 Conclusions 
The following conclusions can be drawn from the 
results of this investigation: 
i. Tablets, upto 7mm in diameter, can empty from 
the fed stomach, in an apparently linear 
fashion. There is an increase in variability 
of emptying as tablet size increases, but no 
significant difference in gastric emptying due 
to the size of the tablets. 
ii. The energy content of the breakfast consumed, 
has a marked effect on the rate of gastric 
emptying of the tablets. 
iii. Tablet size does not influence small intestine 
transit, and colon entry. 
iv. The solid content of the meal consumed may 
have an influence on ileocaecal transit. 
Table 5.2a 
Tablet size 
Time (min) 
0 
15 
30 
45 
60 
75 
90 
105 
120 
160 
190 
220 
250 
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Mean (s.e.m) gastric emptying for the 
light breakfast group - %activity 
remaining in the stomach. 
3mm 4mm 
100 100 
95(4) 90(10) 
95(4) 83(10) 
90(4) 74(10) 
84(13) 59(18) 
80(13) 39(18) 
78(11) 27(16) 
66(11) 12(4) 
40(11) 8(4) 
13(8) 0 
10(8) 0 
1 0 
0 0 
5mm 
100 
100 
86(8) 
77(8) 
65(6) 
54(6) 
32(9) 
15(4) 
5(4) 
0 
0 
0 
0 
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Table 5.2b Mean (s.e.m.) colon entry for the light 
breakfast group - % activity remaining in 
the colon. 
Tablet size 3mm 4mm 5mm 
Time (min) 
105 0 0 0 
120 0 1 0 
160 0 21(17) 0 
190 0 30(17) 0 
220 17(13) 31(25) 8(7) 
250 36(13) 49(25) 29(15) 
290 77(2) 84(8) 72(17) 
320 90(2) 94(8) 83(17) 
350 93(5) 98(1) 86(11) 
390 98(2) 100 93(5) 
435 100 100 100 
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Table 5.3a Mean (s.e.m) gastric emptying for the 
heavy breakfast group - %activity 
remaining in the stomach. 
Tablet size 3mm 4mm 
Time (min) 
0 100 100 
15 100 87(5) 
30 100 79(5) 
45 100 78(5) 
60 95(4) 74(15) 
75 95(4) 72(15) 
90 95(4) 71( 15) 
105 85(4) 70(15) 
120 69(8) 47(20) 
160 58(8) 38(20) 
190 53(8) 35(15) 
220 43(8) 25(15) 
250 31(9) 20(16) 
290 15(9) 13(16) 
320 9(5) 9(6) 
350 6(2) 8(6) 
390 5 8(6) 
435 5 8(6) 
510 5 8 (6 ) 
570 5 3 
640 0 0 
5mm 
100 
100 
96(2) 
96(2) 
93(3) 
90(3) 
88(3) 
85(3) 
75(6) 
54(6) 
53(2) 
49(2) 
38(7) 
24(7) 
20(7) 
16(7) 
16(7) 
16(7) 
11(5) 
8(5) 
0 
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Table 5.3b Mean (s.e.m.) colon entry for the heavy 
breakfast group - %activity remaining in 
the colon. 
Tablet size 3mm 4mm 5mm 
Time (min) 
160 0 0 0 
190 0 3 0 
220 0 4 8 
250 7(5) 4 10(8) 
290 10(5) 38(9) 24(8) 
320 29(5) 60(10) 36(16) 
350 41(20) 69(10) 59(13) 
390 49(20) 74(10) 67(13) 
435 63(20) 82(10) 84(7) 
510 88(9) 86(11) 84(7) 
570 88(9) 86(11) 84(7) 
640 88(9) 86(11) 84(7) 
Table 5.4 
Subject 
L 1 
I 
G 2 
H 
T 3 
mean 
s.e.m. 
H 4 
E 
A 5 
V 
Y 6 
mean 
s.e.m. 
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Lag time and Gastric emptying (St50%) 
values for the light and heavy breakfast 
studies. 
3mm 4mm 5mm 
Lag St50% Lag St50% Lag St50% 
(min) (min) (min) 
15 85 5 95 15 70 
90 113 5 35 30 73 
60 143 30 67 20 83 
52 114 13 66 22 75 
20 14 7 14 4 3 
45 250 5 23 45 235 
105 207 35 275 105 243 
90 123 75 167 15 157 
80 193 38 155 55 212 
15 30 17 60 22 22 
Table 5.5 
Subject 
L 1 
I 
G 2 
H 
T 3 
mean 
s.e.m. 
H 4 
E 
A 5 
V 
Y 6 
mean 
s.e.m. 
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Small intestine transit (SIT) data for 
the light and heavy breakfast studies 
3mm 4mm 5mm 
SIT SIT SIT 
(min) (min) (min) 
175 178 252 
164 118 167 
77 188 242 
139 161 220 
25 18 22 
205 300 158 
183 100 102 
197 110 136 
195 170 132 
5 53 13 
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Table 5.6 Colon entry (Ct50%) and MCt values 
for the light and heavy breakfast studies. 
3mm 4mm 5mm 
Ct50% MCt Ct50% MCt Ct50% Met 
(min) (min) (min) 
Subject 
L 1 260 330 273 315 267 300 
I 
G 2 277 360 153 255 240 285 
H 
T 3 220 495 255 360 325 420 
mean 252 395 227 310 277 335 
s.e.m. 14 41 31 25 20 35 
H 4 455 555 323 450 393 >640 
E 
A 5 390 >580 375 >640 345 >640 
V 
y 6 320 420 277 390 293 360 
mean 388 325 344 
s.e.m. 32 23 24 
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Figure 5.6 
Histogram plots showing the distribution 
of tablets in different regions of the 
gastrointestinal tract after a light breakfast. 
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Figure 5.7 
Histogram plots showing the distribution 
of tablets in different regions of the 
gastrointestinal tract after a heavy breakfast. 
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Table 5.7a Mean (s.e.m) gastric emptying for the 
medium breakfast group - %activity 
remaining in the stomach. 
Tablet size 5mm 6mm 7mm 
Time (min) 
0 100 100 100 
20 95(3) 98(2) 95(3) 
35 94(3) 91( 6) 80(9) 
50 87(3) 91(6) 66(11) 
65 85(4) 87(6) 60(13) 
80 82(5) 86(5) 54(15) 
95 77(8) 78(8) 52(16) 
110 77(8) 69(11) 46(16) 
125 73(7) 69(11) 41(17) 
155 48(6) 58(12) 32(17) 
185 24(7) 38(11) 28(15) 
215 11(8) 24(12) 21(11) 
245 7(6) 12(7) 17(10) 
290 7(6) 9(5) 9(6) 
320 . 7 (6 ) 9(5) 9(6) 
350 7(6) 7(4) 9(6) 
380 5 ( 5 ) 3(2) 6(5) 
410 5(5) 3(2) 6(5) 
455 5(5) 3(2) 6(5) 
500 3(2) 3 ( 2 ) 6(5) 
545 0 1 6(5) 
605 0 0 6(5) 
665 0 0 6(5) 
725 0 0 6(5) 
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Table 5.7b Mean (s.e.m.) colon entry for the medium 
breakfast group %activity remaining in 
the colon. 
Tablet size 5mm 6mm 7mm 
Time (min) 
95 0 0 0 
110 0 0 9(8) 
125 0 0 9(8) 
155 2(2) 0 17(14) 
185 5(5) 0 20(14) 
215 6(5) 6(5) 25(14) 
245 9(5) 25(9) 38(18) 
290 34(12) 34(13) 56(14) 
320 50(13) 46(12) 65(16) 
350 65(12) 65(16) 68(15) 
380 72(13) 66(16) 75(14) 
410 72(13) 70(15) 80(13) 
455 92(4) 79(11) 80(13) 
500 93(3) 79(11) 89(6) 
545 93(3) 89(6) 89(6) 
605 100 97(2) 95(5) 
665 100 97(2) 95(5) 
725 100 98(2) 95(5) 
Table 5.8 
Subject 
1 
2 
3 
4 
5 
6 
mean 
s.e.m. 
Lag 
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Lag time and Gastric emptying (St50%) 
values for the medium breakfast study. 
5mm 6mm 7mm 
St50% Lag St50% Lag St50% 
(min) (min) (min) 
10 90 65 105 20 53 
35 143 125 225 95 213 
35 147 10 88 10 123 
10 157 20 237 10 33 
20 225 50 140 125 265 
125 165 155 178 35 60 
39 155 71 162 49 125 
16 16 22 23 18 35 
• 
Table 5.9 
Subject 
1 
2 
3 
4 
5 
6 
mean 
s.e.m. 
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Small intestine transit (SIT) values for 
the medium breakfast study. 
5rnrn 6mm 7mm 
SIT SIT SIT 
(min) (min) (min) 
190 153 247 
292 292 272 
300 155 104 
113 206 77 
60 115 128 
145 135 200 
183 176 171 
36 24 30 
Table 5.10 
-192-
Colon entry (Ct50%) and MCt values 
for the medium breakfast study. 
Smm 6mm 7mm 
Ct50% MCt Ct50% MCt Ct50% MCt 
(min) (min) (min) 
Subject 
1 280 605 258 410 300 410 
2 435 60S 517 725 485 605 
3 335 380 243 380 227 243 
4 270 455 443 >725 110 150 
5 285 605 255 605 393 >725 
6 310 380 313 350 260 320 
mean 319 505 338 296 
s.e.m. 23 42 43 49 
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Figure 5.10 
Histogram plots showing the distribution 
of tablets in different regions of the 
gastrointestinal tract after a medium breakfast. 
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6.1 Introduction 
In chapter 5, I presented the results of a study 
to evaluate the gastrointestinal transit of tablets, 
with an emphasis on tablet size. In this chapter I 
shall discuss the results of a similar study, with an 
emphasis on the colon transit of tablets. The 
significance of investigating the transit of dosage 
forms through the colon has been previously discussed 
(Section 1.5). 
It is generally accepted that, due to its small 
absorptive area, the colon is not a major site of drug 
absorption (Section 1.5). However, it has been 
postulated that, the absorption of drugs in the colon 
must be greater than has been commonly believed (255). 
This is conceivable, considering that CR systems 
achieve extended absorption profiles, even when the 
dosage form is unlikely to be in the small intestine. 
The slow transit of dosage forms through the colon 
would prolong contact between the system and the 
absorptive surface, resulting in a greater proportion 
of drug being absorbed than would be predicted. This 
has been illustrated in a combined bioavailabilty and 
transit study, conducted in dogs. Dogs that retained 
the multiple unit formulation in the colon for the 
longest time, exhibited the highest bioavailability of 
drug (420). Extensive absorption of drug in the colon 
was considered probable. A similar study conducted in 
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man, reported that a large percentage of ibuprofen was 
absorbed while the dosage form was in the colon (421). 
As mentioned before, few studies have been 
designed to specifically explore the colon transit of 
dosage forms. Work by Hardy et al (315) has suggested 
a relationship between particle size and transit 
through the colon. Another study to evaluate the GI 
transit of an osmotic device, also suggests particle 
size is a determinant of colon transit (250). The 
osmotic device (OSMET, 25mm x 7mm) usually traversed 
the colon ahead of the released solution. 
The design of dosage forms for selective drug 
delivery to the colon has attracted much attention 
(section 1.5). Many studies have considered the 
delivery of corticosteroids (eg. bec10methasone) for 
use in ulcerative colitis, to the large bowel, via the 
mouth (422). The rational design of such systems 
requires extensive evaluation of the colon transit of 
dosage forms. It was, therefore, considered 
appropriate to conduct a study designed to investigate 
the transit of tablets through the colon. 
6.2 Materials and Methods 
The investigation was conducted on three 
consecutive days, which enabled both the total transit 
of the tablets, and the dispersion of tablets in the 
colon after regular daily dosing to be monitored. In 
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order to make a comparison with the previous studies, 
Smm tablets were used in this investigation. 
6.2.1 Preparation of Formulations 
The tablets were prepared as described in the 
previous chapter. However, since the study was 
conducted over three days, indium-Ill (half-life 2.8 
days) was used to label the tablets. Amberlite IR120 
(BOH) cationic resin, was washed and prepared as 
described in Section 2.2.1. Milled resin was labelled 
by soaking in a solution of indium chloride (Amersham 
International) and recovered as before. 
A simple in vitro dissolution test was performed 
on each batch of labelled and coated tablets. Five 
tablets, were added to a beaker containing SOml O.lN 
Hel at room temperature. The contents were stirred 
using a magnetic stirrer and "flea". The tablets were 
removed at regular intervals, and activity measured as 
described in Section 2.2.1. In each case not more than 
2% of radiolabel was lost after six hours. Thus, the 
tablet coating prevented any substantial leaching out 
of the isotopes. Copping (347) reported a total loss 
of 3.7% indium activity from labelled resin soaked in 
solutions ranging from pH 1-14. Indium-Ill is not 
significantly absorbed from the GI tract (423), and 
thus it will not accumulate in any particular organ. 
This makes it more difficult to confirm the integrity 
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of the indium label in vivo. The technique of pertubed 
angular correlation (239) could be used, but this 
requires more than one gamma camera, thus precluding 
its use. Christensen (198) has described an 
alternative method to determine the binding of 
indium-Ill to resin in vivo. A batch of resin pellets 
was half labelled with technetium-99m and the other 
half with indium-Ill. Using the dual isotope facility 
of the gamma camera, the gastric emptying of the 
pellets could be measured simultaneously. The pellets 
had a similar pattern of emptying. The integrity of 
the technetium label was confirmed by monitoring both 
the thyroid and bladder. Differences in gastric 
emptying between the pellets would suggest the loss of 
the indium label. Since there was no difference in 
emptying, it was concluded that the indium remained 
bound to the resin. Thus, although no specific check 
in vivo was made in the present study, the integrity of 
the indium label was assumed on the strength of the 
above result. 
6.2.2 In vivo Study 
The study was approved by the Ethical Committee of 
the University of Nottingham, and conducted in 
accordance with the declaration of Helsinki Guidelines 
for Ethics in Research. Approval to administer 
radiopharmaceuticals was obtained from the DHSS. 
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Five, healthy male volunteers, age range 20-25, 
height range 1.70-l.82m, weight range 57-83kg, 
participated with informed consent. Each subject 
abstained from alcohol for 24h, and had fasted for 10h 
prior to each study day. The subjects did not smoke, 
and were not on medication. On the morning of each day 
of the study, the subjects took five 5mm tablets 
99m together with 200ml Tc-DTPA labelled water (3MBq). 
The labelled water enabled ready identification of the 
stomach and colon. The subjects remained fasted before 
administration of the tablets to allow a more rapid 
transit to the colon, and provide data for comparison 
with the previous 5mm tablet fed studies. Each dose of 
tablets had an activity of about IMBq. The total 
radiation dose absorbed by the subjects was estimated 
as 0.533mG/MBq for the stomach, 1.066mG/MBq for the 
small intestine, and 0.128mG/MBq for the whole body 
(133,350). Anterior and posterior images, each of 60s 
duration, were taken at regular intervals, using a 
gamma camera (General Electric Maxicamera, Type II) 
having a 40cm field of view and fitted with a medium 
energy (200 keV) parallel hole collimator. The 
subjects stood in front of the camera for imaging and 
were asked to keep body movements to a minimum during 
imaging. During the study, the subjects remained in an 
upright position, sitting/standing. The images were 
recorded, and stored on computer (Nodecrest). 
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Anatomical reference markers containing indium-Ill, 
were taped to the skin, anteriorly and posteriorly, 
over the liver to the right of the stomach. At about 
2.5h after dosing the subjects were given a drink of 
orange juice. A standard light lunch consisting of one 
ham roll and l50ml orange juice, was taken after about 
4h. An evening meal of steak, chips, peas, and 
cheesecake was taken about IOh after dosing. 
The recorded images were analysed by drawing 
regions of interest around the position of the stomach 
and colon, as described previously (Section 2.2.2). 
The activity in these regions was quantified, and then 
corrected for background activity and radioactive 
decay. The error due to the variation in depth of 
radionuclide in the stomach and colon, was corrected by 
calculating the geometric mean of corresponding 
anterior and posterior views (216). Careful 
examination of the colon images enabled the individual 
tablets to be seen and counted. The dispersion of the 
tablets provided a good outline of the colon, allowing 
identification of the various regions. 
The study was repeated using the same protocol on 
the following two days. A record of bowel habits was 
kept for the period of the study. The subjects did not 
complain of any untoward side-effects during each study 
day. 
6.3 Results and Discussion 
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6.3.1 General Discussion 
The data for the investigation have been 
quantified in a number of different ways, and 
representative examples are given. The St50%, SIT, 
Ct50% and MCt values are presented in Tables 6.1-6.5. 
Gastric emptying profiles and colon entry curves are 
.shown in Figures 6.1-6.5. Representative scintiscans, 
which illustrate the various phases of transit, are 
presented in Figure 6.6. Diagrams to illustrate the 
transit of the tablets in the colon are shown in 
Figures 6.7, 6.9 and 6.11. Histogram plots, which also 
demonstrate the transit of the tablets in the colon are 
given in Figures 6.8, 6.10 and 6.12. 
Generally, the tablets emptied from the stomach 
rapidly and as a bolus. This bolus emptying probably 
relates to the phase 2/phase 3 activity of the MMe, and 
was observed in the pellet studies described in 
previous chapters. Feely et al (410) also reported on 
the bolus emptying of mini-matrix tablets in fasted 
subjects. In some cases, especially on day 3, the 
tablets began to empty only after a lag phase (eg. 
subject 5, Figure 6.2). This lag must relate to the 
quiescent MMC activity of phase 1. Subject 2 also 
exhibited a long lag phase (Figure 6.3), before the 
tablets began to empty. However, emptying of the 
tablets was interrupted at about 240min, which 
coincides with lunch. A second lag phase is then 
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apparent, before the bolus emptying of the remainder of 
the tablets. This example illustrates the cessation of 
the MMC contractions by the ingestion of food. 
Unfortunately, ingestion of food before the tablets had 
emptied from the stomach, introduced an extra variable 
which applied only to subject 2. This demonstrates a 
problem commonly associated with such studies, which 
should aim to reduce all experimental variables but 
maintain a real life situation. The St50% values are 
similar to previously cited results, and also to the 
pellet data presented in previous chapters. A paired 
Student t test on the St50% values for the three days 
shows no significant difference (p>O.l) between the 
results. It is interesting to note, that the 
variability of the data (s.e.m. value) on day 3 is 
greater than on the first two days. This is due to the 
St50% value for subject 2, since the variability is 
reduced if this value is not included (mean 83mint2l). 
The gastric emptying profiles (Figure 6.4) illustrate 
the effect that this result has on the mean GE values, 
with the day 3 curve extending over a longer period of 
time. A greater variability in gastric emptying data 
would have been expected, since the probability of the 
subjects being in" the same phase of the MMC is small. 
Park et al (249) monitored the gastric emptying of a 
series of capsules (diameter 4.7-9.5mm, length 
9.8-1.76mm) and spheres (diameter 6.0-l.27mm) in fasted 
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subjects. They concluded that gastric emptying was a 
very variable process in fasted subjects, and was 
governed by t,he time of ingestion of the dosage form in 
relation to the active phases of the MMC. Gastric 
residence times varied between 5->140min. However, in 
another study, the gastric emptying of a single tablet 
(17x4mm), in fasted old and young subjects, did not 
exhibit a large interindividual variation (s.e.m. 
7-l3min) (417). Jonsson et a1 (416) obtained mean 
gastric emptying data of 60min for 3mm tablets, and 
45min for 14mm tablets. This result suggests that 
tablet size is not a determinant of gastric emptying in 
the fasted state. Gruber et a1 (424) found that >90% 
of administered particles are emptied from the stomach 
by one MMC. The remainder require no more than two 
cycles of the MMC. They also concluded that size, 
density and surface characteristics do not influence 
gastric emptying in fasted dogs. 
A comparison of the results with the 5mm tablet 
data for the light, medium, and heavy breakfast 
studies, further exemplifies the effect of food and the 
activity of the MMC on gastric emptying. The St50% 
values for the present study are similar to the St50% 
values of the light breakfast, but the pattern of 
emptying is different. In the fasted state, the 
tablets empty as a bolus, whereas after the breakfast, 
emptying is slightly more transitory (Figures 6.4 and 
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6.5). The difference between the fasted data and the 
medium and heavy breakfast results is well illustrated 
by the gastric emptying profiles. Smith and Feldman 
(415) also noted a pronounced effect on the gastric 
emptying of 10mm tablets due to food. Tablets 
administered to fasting subjects emptied rapidly, 
whilst those administered after a meal had a longer 
gastric residence. The bolus emptying of dosage forms 
from the fasted stomach is of significance to the 
performance of multiple unit systems. These systems 
are designed to spread through the small intestine, by 
virtue of their gastric emptying. However, in the 
fasted state, the sub-units could empty as a bolus and 
traverse the small intestine as a bolus, thus 
compromising their performance. 
The SIT values are similar to the previous pellet 
data, and in close agreement with the mean small 
intestine transit value for dosage forms (304). 
Subject 4 exhibits a very short SIT, on more than one 
occasion, which may be due to a powerful phase 3 
contraction accelerating the tablets to the colon. It 
was apparent from the recorded images that, the tablets 
traversed the small intestine as a bolus. There is no 
significant difference between the results of the three 
study days (p>O.l). These SIT values are similar to 
the previous 5mm tablet results, which again confirms 
the invariable nature of small intestine transit. 
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The CE data are also in close agreement with the 
previous 5mm light breakfast results, with no 
significant difference between the three days. The 
transit of the tablets through the colon will be 
discussed below. 
6.3.2 Colon Transit 
It is evident from the colon entry curves (Figures 
6.1-6.4) that, entry of the tablets into the colon 
occurred as a bolus. As mentioned before, entry of 
material as a bolus is not necessarily due to MMC 
activity. Steep colon entry curves are indicative of 
clumping at the ICS, followed by bolus entry into the 
colon (99). Clumping was apparent on the recorded 
images and is illustrated in Figure 6.6. The tablets 
did not remain at the ICS for extended periods, 
although subject 1 on day 3 did exhibit a long 
residency' at the ICS. This is exemplified by the long 
SIT value. The mean colon entry curves (Figure 6.4) 
are similar to the profiles for the Smm tablets taken 
after a light breakfast (Figure 6.5). The curve for 
day 3 suggests a less rapid rate of entry, which can 
partly be explained by the long gastric residence of 
subject 2. This would shift the curve to the right. 
Nevertheless, the tablets, for this subject, did enter 
the colon as a bolus. The stagnation of the tablets at 
the ICS, in subject 1, would also broaden the colon 
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entry curve. Further similar studies would indicate 
the frequency of extended stagnation at the rcs, in 
fasted subjects, and determine the generic pattern of 
colon entry. The similarity between the light 
breakfast and fasted (day 1 and 2) colon entry curves, 
provides more evidence that meal residue may influence 
transit through the lCS. It is unlikely that, the 
residue from lunch would have affected colon entry, 
since entry usually began before or within an hour of 
lunch. Furthermore, the solid content of the meal was 
relatively small. There was also no demonstrable 
relationship between the ingestion of food and either 
colon entry or transit through the colon. Thus, whilst 
ingestion of food normally causes an increase in 
colonic activity, the "gastrocolic" reflex (101), this 
increased activity does not necessarily result in 
aboral movement of colonic material. 
The transit of the tablets through the colon is 
best illustrated by the results for subjects 1, 2, and 
3 (Figures 6.7-12). The tablets usually remained as a 
bolus in the region of the caecum, began to disperse as 
they progressed further up the ascending colon, 
transverse colon and descending colon, before forming a 
bolus in the sigmoid cOlon/rectum. It has been 
previously noted that dispersive systems, such as 
pellets, become widely distributed within the colon 
(220). A similar dispersion was also seen of a 
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radio1abe1 marker released from an osmotic device 
(OSMET) (250). 
Subject 1 exhibited an extremely slow transit 
through the colon, with 15 tablets remaining in the 
colon at the end of day 3. These tablets were 
distributed throughout the colon. In contrast, subject 
2 exhibited a faster rate of transit. Most of the day 
2 tablets, had reached the sigmoid colon 420min after 
entering the colon, and were evacuated before day 3. 
Subject 3 appeared to have an intermediate rate of 
transit. Three of the day 1 tablets had been evacuated 
at the start of day 2. It is interesting to note that, 
the remaining two tablets were only in the descending 
colon and not in the sigmoid colon. This suggests a 
mass movement of material which evacuated the three 
tablets. The two remaining tablets were evacuated 
before day 3. Subjects 4 and 5 also exhibited an 
intermediate rate of transit. It is evident from the 
histograms that, total transit times of the tablets 
(mouth to anus) ranged from about ISh (subject 2, day 2 
tablets) to more than 72h (subject 1). Hardy et al 
(315) reported total transit times of l7-72h, for a 
pellet formulation given to fasted subjects. John et 
a1 (425) obtained a median mouth to evacution time of 
27.4h, for a single unit system (OROS), in fasted 
subjects. Individual times, however, ranged from 
5.1-5S.3h. Transit was measured by recovering the unit 
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in the faeces. It has been suggested that very short 
transit times (uptb 6h), may relate to a vegetarian 
diet (418). Further studies detailing the normal diet 
of the subjects would provide the required evidence for 
this suggestion. 
The histograms suggest that transit of the tablets 
was not a continuous process, but was interspersed with 
periods of little movement. Similar observations were 
made by Hardy et al (315). Oefaecation did not 
generally result in a major progression of the tablets, 
except to evacuate those tablets in the sigmoid 
colon/rectum. As mentioned above, a mass movement 
appears to have occurred in subject 3. Mass movement, 
at the time of defaecation, is also suggested for 
subject 2 on day 2 (Figure 6.10)1 tablets progressed 
rapidly from the transverse colon down to the sigmoid 
colon. John et al (425) did not notice a relationship 
between total transit times and the frequency of bowel 
movements. 
The present results provide further substance to 
previous comments regarding COOS designed for drug 
delivery to the colon (315). The duration of gastric 
emptying and small intestine transit suggests that, 
drug should not be released from the system for about 
5h after administration to fasted patients. Release of 
drug, from a dispersive system, over the next few hours 
would distribute throughout the proximal and transverse 
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colon. However, the period of drug release is 
restricted by the apparent intersubject differences in 
colon transit times. A multiple unit system given on a 
once daily basis, would be sufficiently dispersed in 
the colon to provide adequate local delivery of drug 
for the treatment of common colonic diseases. The 
results of this study are also of relevance to the 
general design of CDDS. Total transit times of less 
than 24h makes once daily dosing redundant, even if 
drugs are extensively absorbed in the colon. 
Furthermore, it is still necessary to determine the 
degree of biotransformation of drugs that occurs in the 
colon, and more importantly, the extent of drug 
absorption that does occur in the colon. Conventional 
bioavailability studies, combined with the technique of 
gamma scintigraphy would be extremely suitable for such 
investigations. Efforts should, therefore, be 
continued in 'devising systems which have a prolonged 
gastric residence, especially in the fasted state. 
Food may extend gastric residence, but this is neither 
a practical nor pharmaceutical option, and thus other-
strategies are required. 
6.4 Conclusions 
The following conclusions can be drawn from the 
results of this investigation: 
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i. Tablets (5x5mm) emptied rapidly and as a 
bolus from the fasted stomach. Transit 
through the small intestine was also as a 
bolus. 
ii. The tablets amassed at the ileocaeca1 
sphincter, before entering the colon as a 
bolus. Residency at the ileocaeca1 
sphincter was of a short duration. 
iii. The rate of transit through the colon was 
very different between subjects. However, 
in all subjects, the tablets did disperse 
throughout the colon. 
iv. There was no relationship between either the 
ingestion 'of food or bowel habits, and the 
movement of the tablets in the colon. 
Table 6.1 
Study day 
Time (min) 
0 
20 
40 
60 
80 
120 
160 
200 
240 
280 
320 
360 
420 
480 
540 
600 
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Mean (s.e.m) gastric emptying values 
- %activity remaining in the region. 
1 2 3 
100 100 100 
67(16) 80(18) 95(3) 
36(15) 17(16) 82(8) 
24(16) 0 50(19) 
14(13) 0 47(18) 
0 0 33(19) 
0 0 31(18) 
0 0 31(18) 
0 0 14(8) 
0 0 7(6) 
0 0 7(6) 
0 0 7(6) 
0 0 7(6) 
0 0 7(6) 
0 0 7(6) 
0 0 0 
Table 6.2 
Study day 
Time (min) 
80 
120 
160 
200 
240 
280 
320 
360 
420 
480 
540 
600 
660 
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Mean (s.e.m) colon entry values 
%activity remaining in the region. 
1 2 
0 0 
0 20(18) 
20(18) 20(18) 
60(22) 20(18) 
60(22) 40(22) 
75(17) 60(22) 
100 97(2) 
100 100 
100 100 
100 100 
100 100 
100 100 
100 100 
3 
0 
0 
16(14) 
33(19) 
33(19) 
39(22) 
52(20) 
60(19) 
86(8) 
94(6) 
94(6) 
94(6) 
94(6) 
Table 6.3 
Subject 
1 
2 
3 
4 
5 
mean 
s.e.m. 
Lag 
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Lag time and Gastric emptying (St50%) 
values. 
Day 1 Day 2 Day 3 
St50% Lag St50% Lag St50% 
(min) (min) (min) 
0 35 0 10 0 43 
0 10 20 30 200 230 
0 30 20 30 20 45 
0 20 20 30 0 100 
0 2B 20 50 40 145 
0 25 16 30 52 113 
4 4 6 38 7B 
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Table 6.4 Small intestine transit (SIT) values. 
Day 1 Day 2 Day 3 
SIT SIT SIT 
(min) (min) (min) 
Subject 
1 135 210 362 
2 252 230 173 
3 255 270 145 
4 115 70 45 
5 167 253 167 
mean 185 207 178 
s.e.m. 29 36 51 
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Table 6.5 Colon entry (Ct50%) and MCt values. 
Day 1 Day 2 Day 3 
Ct50% MCt Ct50% MCt Ct50% Met 
(min) (min) (min) 
Subject 
1 170 210 220 240 405 480 
2 262 320 260 280 403 
3 285 320 300 320 190 360 
4 135 160 100 120 145 200 
5 195 200 303 360 312 420 
mean 209 242 237 264 307 
s.e.m. 25 29 38 41 51 
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7.1 Future Work 
The studies described in this thesis form part of a 
general programme to investigate the gastrointestinal 
transit of dosage forms. These studies were designed to 
evaluate the influence of both physiological and 
pharmaceutical parameters on gastrointestinal transit. 
The ultimate aim is to rationalise the performance in 
~ ~ of oral dosage forms, and subsequently design 
physiologically competent coos. The obligation of the 
pharmaceutical industry to define the gastrointestinal 
transit of all new formulations, in fed and fasted 
subjects, has been suitably expressed (426). 
The majority of studies to date, have been conducted 
using healthy subjects. Whilst these studies provide a 
basic understanding of gastrointestinal transit, their 
absolute relevance to the clinical environment is fairly 
questionable. Differences in gastrointestinal motility 
between patients and healthy individuals, may have a 
significant effect on the transit and dispersion of COOS. 
Future studies, conducted with patient volunteers, would 
be of considerable value. Similarly, most studies have 
mainly considered the transit of placebo formulations. 
Future work should also concentrate on combined 
bioavailability and transit studies. These would provide 
information on site-specific absorption, the effect of 
drugs on motility, and the extent of drug absorption in 
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the colon. Naturally, the ethical restraints of such 
studies should be realised. 
The need to regulate the gastric emptying of dosage 
forms has been expressed on a number of occasions. The 
two methods investigated in this thesis, the size of 
tablets and mucoadhesion, did not prove successful. The 
impracticality of using tablet size as a controlling 
factor has already been mentioned. Further work is 
required to prove the usefulness of mucoadhesives. 
Coated systems, as opposed to admixtures, may be more 
successful. Two other strategies which merit 
investigation are: 
i. incorporate fatty acids (330)/tryptophan 
(427), which are active at specific duodenal 
receptors, into formu1ationsJ the quantities 
required to produce a physiological response, 
in man, may prohibit their use1 
ii. the use of gel forming materials, such as guar 
gum, to increase gastric viscosity (31), 
however, the quantities required to slow 
gastric emptying may also restrict their use. 
Further studies are also required to investigate 
the transit of dosage forms through the i1eocaecal 
sphincter and colon • 
A major drawback to transit studies is the sample 
size, in each study. Criticism has been drawn that the 
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small number of subjects participating in each study, 
prevents any definitive conclusion being made from the 
study. However, as more studies are conducted, the 
accumulated data should provide a representative 
principle for the transit of dosage forms through the 
gastrointestinal tract. 
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